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ABSTRACT
Background: Cancer patients undergoing chemotherapy often experience chemotherapyinduced-peripheral-neuropathy, which reportedly causes gait disturbances that may increase their
risk for falls. Falls are a significant event because they have been linked to serious injuries and
disabilities, loss of independence, and increased mortality rates. Purpose: The purpose of this
study was to assess whether chemotherapy-induced peripheral neuropathy is associated with
spatiotemporal gait adaptations in posttreatment adult cancer survivors when compared to
healthy, disease-free, age and morphologically matched controls. Methods: In a quasiexperimental design, 16 subjects participated in the present study. There were 8 CIPN subjects
between the ages of 50–70 years of age who had a histologically confirmed stage 2–3 breast or
colorectal cancer diagnosis with a confirmed treatment plan consisting of taxane- or oxaliplatinbased chemotherapy. Controls consisted of 8 age and morphologically matched subjects. The
primary outcome consisted of spatiotemporal gait parameters as computed using the GAITRite
walkway and software. Secondary outcomes consisted of determining fall risk using the Timed
Up & Go test. Results: Gait velocity for CIPN patients (110. 75 cm/s, SD = 26.79), was
significantly slower than gait velocity of the controls (147.79 cm/s, SD = 11.69). Step length
was significantly shorter for CIPN (53.92 cm, SD = 23.55) when compared to the controls (77.15
cm, SD = 5.28). Lastly, CIPN participants had a significantly higher TUG Score (12.33 s, SD
6.25) compared to the controls (6.62 s, SD = 1.10). Conclusion: Cancer patients with CIPN
displayed a slower walking velocity and shorter step length compared to healthy age and
morphologically matched controls. Additional gait patterns, such as step time, step length, base
of support, swing time, single support time, and double support time, were not significantly
different. Also, the mean TUG score for CIPN patients were not only significantly greater than
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the controls, but were also above the clinical fall risk cut off of 10.7 s, indicating fall risk. While
gait speed and step length were the only significant gait variables, as noted in the literature they
are key indicator for fall risk.
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Chapter I

INTRODUCTION
Chemotherapy-induced peripheral neuropathy (CIPN) is generally classified as a series of
neuromuscular symptoms, both sensory and motor in nature, that results from nerve damage
caused by the neurotoxic effects of chemotherapy drugs for the treatment of cancer (Park et al.,
2013; Visovsky, 2003). It is estimated that at least 30% of patients who receive paclitaxel,
docetaxel, bortezomib, thalidomide, or oxaliplatin will develop a degree of chemotherapyinduced peripheral neuropathy. The characteristics of CIPN depend upon the specific
chemotherapy agent used, as well as when the agent is introduced in the treatment protocol and
the dosage amount (Airley, 2009).
Symptoms of CIPN may be acute, mild or severe, transient or chronic, depending upon
the treatment regime and dose of the agents and may manifest in a variety of ways, involving
sensory and motor symptoms (Park et al., 2013; Postma & Heimans, 2000; Wilkes, 2007).
Sensory signs and symptoms may include numbness, tingling, burning, pain, ataxia, loss of deep
tendon reflex, and reduced sense of touch, vibration, and proprioception. Motor symptoms may
include weakness, balance disturbances, and difficulty performing fine motor skills and a
diminished or absent deep tendon reflex. Motor symptoms are less frequent due to the
neurotoxic agent’s inability to cross the blood–brain barrier in concentrations significant to cause
harm (Bakitas, 2007; Murillo, Cox, & Oholendt, 2008; Park et al., 2013; Visovsky, Collins,
Abbott, Aschenbrenner, & Hart, 2007; Wilkes, 2007). The autonomic system may also be
affected, resulting in constipation, urinary retention, sexual dysfunction, and altered blood
pressure (Bakitas, 2007; Visovsky et al., 2007; Wilkes, 2007).
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Sensory changes in the toes and feet are usually first to be noticed, followed by in the
fingers and hands, progressing in a distal–proximal fashion to the ankles and wrist in a stockingglove manner (Park et al., 2013; Wolf, Barton, Kottschade, Grothey, & Loprinzi, 2008).
Chemotherapy-induced peripheral neuropathy symptoms are most commonly distributed in a
bilateral and symmetrical pattern. It is not uncommon for CIPN symptoms to intensify after the
neurotoxic agent has been discontinued; this is referred to as coasting and is the result of
cumulating concentrations of the neurotoxic agent within the body system. In some instances,
CIPN symptoms may occur gradually over a prolonged period. But it is not uncommon for
CIPN symptoms to appear suddenly and intensely (Wilkes, 2007).
The impact of CIPN varies and, thus, affects patients differently. Cumulatively, CIPN
symptoms may negatively alter a patient’s ability to perform routine activities, functions, and
behaviors. Specifically, patients experiencing CIPN symptoms will often report difficulties such
as with sleeping, driving, standing, walking, climbing stairs, balancing, opening containers,
holding onto things, cooking, cleaning, flipping pages of paper, wearing certain shoes and
jewelry, exercising, and socializing (Speck et al., 2012; Tofthagen, 2010). The most common
symptoms reported include burning, muscle aches, and sensitivity to cold (Tofthagen, 2010).
Patients with CIPN reported a variety of symptoms in their feet, which included the feelings of
“ice cold,” “walking on hot coals,” and “sandpaper on the bottom of your feet” (Tofthagen,
2010, p. E25).
The exact cause of CIPN remains elusive. However, it is currently understood that
chemotherapy agents will often inflict their neurotoxic effects on axons and cell bodies of dorsal
root ganglion neurons, resulting in axonal damage, which is characterized by a decrease in
intraepidermal nerve fiber density and terminal arbor degeneration (Han & Smith, 2013).
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Chemotherapy agents will also exert their toxicity on mitochondria, causing them to
become swollen and vacuoled, as well as causing oxidative stress, resulting in inflammation.
Pathologically, the dorsal root ganglion neurons and surrounding satellite cells may negatively
alter the expression of various ion channels, neurotransmitters, and receptors, as well as exhibit
altered gene expression. The mitochondrial dysfunction and IENF loss seem to be directly
correlated to presence of pain. Cumulatively, these changes cause various sensory symptoms,
such as numbness, tingling, burning, pain, and reduced sense of touch, as well as motor
symptoms, such as weakness, balance disturbances, and difficulty performing fine motor skills,
as frequently reported by cancer patients undergoing chemotherapy treatment (Bakitas, 2007;
Han & Smith, 2013; Murillo et al., 2008; Visovsky et al., 2007; Wilkes, 2007).
Although the mechanism that causes CIPN is not well understood, it is apparent that
chemotherapy agents will exert their neurotoxic effects on the body’s neurons, which is the basic
component of the nervous system, and transmit signals throughout the body. Neurons have three
functional classes, which include sensory neurons (also called afferent neurons), motor neurons
(also called efferent neurons) and interneurons, which originate and terminate in the brain or
spinal cord, acting as connections between axons descending and descending within the brain or
spinal cord (Magill & Anderson, 2013). Sensory neurons send neural impulses to the central
nervous system (CNS), whereas motor neurons send neural impulses from the CNS to skeletal
muscle fibers (Magill & Anderson, 2013).
The peripheral nervous system has three functional divisions, which are the sensory
nerves, motor nerves, and the autonomic nerves. The sensory nerves sense touch, pain,
temperature, position, and vibration. The motor nerves are responsible for voluntary movement,
muscle tone, and coordination (Armstrong, Almadrones, & Gilbert, 2005). The small nerve
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fibers are primarily composed of microtubules, which transport proteins throughout the nerve
fiber. Large nerve fibers are primarily composed of neurofilaments, which comprise the axon’s
framework. Sensory nerves terminate at the level of the skin and extend to the dorsal root
ganglion, connecting with either the dorsal column via a large fiber or the spinothalamic tract via
a small fiber in the spinal cord (Armstrong et al., 2005).
The somatosensory system, which consists of muscle spindles, Golgi tendon organs, joint
receptors, and cutaneous receptors, contributes the modulation of spinal pattern generators,
modulation of motor commands, and perception and control of movement through sensory
information. These sensory neurons provide information about mechanical stimuli, temperature
changes, potential damage to the skin, body and limb movement and position, and velocity and
muscle activation (Magill & Anderson, 2013; Shumway-Cook & Woollacott, 2012). Of
particular interest are cutaneous receptors, which consist of mechanoreceptors, thermoreceptors,
and nociceptors, and are located within sensitive areas of the skin with as many as 25,000 per
square centimeter (Shumway-Cook & Woollacott, 2012). Cutaneous sensory receptors provide
information about the body’s orientation within the immediate environment and provide
information necessary for reflexive responses.
Cumulatively, sensory receptors within the somatosensory system provide information
via afferent nerve fibers to the spinal cord, which allows for the modulation of locomotion.
Control of one’s gait may also depend upon afferent information from additional sources,
including the visual, vestibular, and proprioceptive systems (Dietz, 2002; Gandevia & Burke,
1992).
Gait has been defined as a subconscious and highly reproducible movement, that is often
performed daily as one participates in their daily activities. Stable gait requires appropriate
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communication between the neuronal spinal and supraspinal pattern generators, as well as
sensory feedback from visual, vestibular, and proprioceptor systems. Feedback from the sensory
system is believed to provide critical information for the adjustment of stride-to-stride limb
trajectories in order to smooth out unintended irregularities during walking (Dietz, 2002).
Therefore, peripheral sensibility is often reduced in individuals with peripheral neuropathy,
which may negatively affect proprioceptive feedback, thus disrupting normal locomotion and
increased variability in one’s gait (Wuehr et al., 2014).
Although it has been well documented that cancer survivors who are undergoing or have
undergone chemotherapy may experience peripheral neuropathy and gait disturbances, research
regarding the exact changes that have occurred in their gait cycle and cause patients to report
unsteady gait and frequent calls are relatively new and unknown. Alternatively, the effects that
peripheral neuropathy has on gait has been well documented within the diabetic population.
Specifically, it has been demonstrated that individuals with diabetic peripheral neuropathy
generally display a gait that is more conservative and may be characterized by slower walking
velocities and smaller step sizes (Paul, Ellis, Leese, McFadyen, & McMurray, 2009; Wrobel,
Crews, & Connolly, 2009). Similar to chemotherapy-induced peripheral neuropathy (CIPN),
diabetic peripheral neuropathy (DPN) targets both sensory and motor fibers and is progressive in
nature. Large and small diameter nerve fibers are affected, resulting in attenuated sensory nerve
conduction, which includes large fiber thresholds for vibration and joint positions, as well as
neurogenic atrophy due to axonal degeneration of motor fibers (Andersen, Gadeberg, Brock, &
Jakobsen, 1997; Dyck & Thomas, 1999; Horak, Dickstein, & Peterka, 2002)
Individuals with DPN often display altered gait patterns, which may be characterized as
slower, with shortened stride lengths and increased base widths, stride times, and double support
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times when compared to age-matched controls (Andersen et al., 1997; Dyck & Thomas, 1999;
Horak et al., 2002; Shankarappa, Piedras-Rentería, & Stubbs, 2011; Wuehr et al., 2014).
Furthermore, individuals with peripheral neuropathy often display significant increases in
locomotor variability. Not surprising, increased variability in the gait cycle has been found to be
most correlated with falls (Dingwell & Cavanagh, 2001).
Although research indicates that sensory feedback plays a critical role in adjusting the
stride-to-stride limb trajectories in order to smooth out irregularities during unperturbed
movements and safely navigate and maintain balance, when the somatosensory system is
compromised, as in the case of peripheral neuropathy, increased variability arises. Previous
research indicates that increased stride-to-stride variability associated with one’s stride length,
walking speed, and double support time each independently contribute to falling (Dingwell &
Cavanagh, 2001; Gandevia & Burke, 1992; Maki, 1997)
Falling is a significant event, especially for older adults, as falls have been linked to
serious injuries and disabilities, loss of independence, and increased mortality. Twenty-three
percent of falls in adults aged 65–69 result in death, with the rate climbing as high as 50% of
falls resulting in death for adults aged 85 or older. It is estimated that of the 1.6 million new
cancer diagnoses in 2013, 77% were individuals over the age of 55 (Alamgir, Muazzam, &
Nasrullah, 2012). Cancer patients experiencing peripheral neuropathy have reported difficulties
in walking and incidences of falls (Tofthagen, Visovsky, & Berry, 2012). In fact, it’s estimated
quantified that approximately 20% of patients with CIPN may fall, which is a higher percentage
than age-matched controls (Mohile et al., 2009, 2011; Tofthagen, Overcash, & Kip, 2012).
Stone and colleagues (2012) conducted a 6-month prospective study of cancer patients and found
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that 50.3% of the patients fell during the studies follow-up period. More significantly, over onethird of the falls resulted in soft tissue injuries and 3.2% resulted in fractures.
Early research suggests that cancer patients may experience axonopathy and a
compromised somatosensory system as a result of undergoing chemotherapy treatments (Han &
Smith, 2013; Visovsky & Daly, 2004). It has been noted that cancer patients experiencing even
mild peripheral neuropathy after receiving taxane chemotherapy may experience significant
changes in postural stability as a result of their treatment, which may cause the neurotoxic effect
of taxane on the somatosensory systems and the subsequent changes that occur as a result of the
neurotoxicity. Furthermore, while the severity of the peripheral neuropathy experienced by the
participants in this study was mild, the postural instability displayed was comparable to diabetic
individuals diagnosed with severe neuropathy.
In summary, cancer patients undergoing chemotherapy may often experience varying
degrees of chemotherapy-induced peripheral neuropathy (CIPN), which may result in impaired
neuronal function and manifest through a loss of sensation and proprioception, disturbed nerve
conduction velocities, and a reduction in muscle strength (Argyriou et al., 2013; Bakitas, 2007;
Krishnan, Goldstein, Friedlander, & Kiernan, 2005; Murillo et al., 2008; Park et al., 2013;
Visovsky et al., 2007; Wilkes, 2007). Chemotherapy agents have a toxic effect on the
somatosensory component of the nervous system (Stillman & Cata, 2006; Wang, Lehky, Brell, &
Dorsey, 2012; Wickham, 2007). This facet of the nervous system is responsible for modulating
and producing coordinated gait patterns. When impaired, it may result in functional impairments
that lead to walking difficulties, as reported by cancer patients (Shumway-Cook & Woollacott,
2012).
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Research indicates that abnormalities or the observation of variability in gait parameters,
such as cadence, stride length, swing, double support, stride length variability, and swing time
variability, may increase the risk of falling (Toulotte, Thevenon, Watelain, & Fabre, 2006;
Verghese, Holtzer, Lipton, & Wang, 2009). Falling is a significant event for the elderly
population, as falls have been linked to serious injuries and disabilities, loss of independence,
and increased mortality (Alamgir et al., 2012). It is estimated that of the 1.6 million new cancer
diagnoses in 2013, 77% were individuals over the age of 55, and previous research indicated that
20% of patients with CIPN may fall, which is a higher percentage than the age-matched
nondisease control (Alamgir et al., 2012; American Cancer Society, 2013; Mohile et al., 2009,
2011; Tofthagen et al., 2012).
Peripheral neuropathy may also be experienced in diabetic patients, and research suggests
that the symptoms and pathophysiology of diabetic peripheral neuropathy (DPN) are similar to
cancer patients with CIPN (Andersen et al., 1997; Dyck & Thomas, 1999; Horak et al., 2002;
Tesfaye & Selvarajah, 2011). These diabetics display altered gait patterns characterized by
slower gait velocities, shorter step lengths, and lower cadences, which may be the result of
altered muscle activation times and velocity, as well as decreased joint mobility (Andersen et al.,
1997; Paul et al., 2009; Savelberg et al., 2010; Sawacha et al., 2009; Thomas & Tomlinson,
1993).
Although CIPN is prevalent in cancer patients undergoing chemotherapy, evidence
suggests that other patient populations, such as diabetics with peripheral neuropathy, may
experience abnormal spatiotemporal gait patterns due to neuropathic symptoms. In turn these
abnormalities may increase the risk of falls, yet surprisingly spatiotemporal gait parameters have
not been studied in cancer patients undergoing chemotherapy (Wallace et al., 2002).
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Statement of the Problem
Chemotherapy agents have a toxic effect on the somatosensory component of the nervous
system, causing many cancer patients to experience chemotherapy-induced peripheral
neuropathy, which may be described as loss of sensation and proprioception, disturbed nerve
conduction velocities, and a reduction in muscle strength (Argyriou et al., 2013; Bakitas, 2007;
Krishnan et al., 2005; Murillo et al., 2008; Stillman & Cata, 2006; Visovsky et al., 2007; Wang
et al., 2012; Wickham, 2007; Wilkes, 2007). This facet of the nervous system is responsible for
modulating and producing coordinated gait patterns and when impaired may result in functional
impairments that lead to walking difficulties, as reported by cancer patients (Shumway-Cook &
Woollacott, 2012). Diabetics commonly experience peripheral neuropathy. The presence of
peripheral neuropathy has been associated with changes in gait patterns and increases in falls in
this population (Andersen et al., 1997; Paul et al., 2009; Savelberg et al., 2010; Sawacha et al.,
2009; Thomas & Tomlinson, 1993). Research indicates that abnormalities in gait parameters
may increase the risk of falling, which is a significant event for the elderly population, as falls
have been linked to serious injuries and disabilities, loss of independence, and increased
mortality (Alamgir et al., 2012; Toulotte et al., 2006; Verghese et al., 2009). Copious amounts
of research demonstrate the importance of the somatosensory system for gait modulation, and
when this system is impaired, significant gait changes occur that increase fall risk. Nonetheless,
insight into changes in gait patters of cancer patients with CIPN remains unknown. Considering
the increased incidence of falls in cancer patients with CIPN, it is paramount to investigate if the
same gait changes occur within cancer patients as with CIPN.
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Purpose of the Study
The purpose of this study was to investigate if changes occur in spatiotemporal gait
parameters of cancer patients who have undergone taxane- or platinum-based chemotherapy
treatments and have been diagnosed with chemotherapy-induced peripheral neuropathy.
Additionally, the level of fall risk associated with the CIPN remains a secondary variable of
interest.
Research Question
1. Do significant changes occur in spatial gait parameters within individuals diagnosed with
CIPN as a result of undergoing either taxane- or platinum-based chemotherapy agents?
2. Do significant changes occur in temporal gait parameters within individuals diagnosed
with CIPN as a result of undergoing either taxane- or platinum-based chemotherapy
agents?
3. Does a significant change occur in fall risk within individuals diagnosed with CIPN as a
result of undergoing either taxane or platinum based chemotherapy agents?
Hypothesis
1. There will be significant differences in spatial gait parameters between individuals
diagnosed with CIPN and age- and morphologically matched controls.
2. There will be significant differences in temporal gait parameters between individuals
diagnosed with CIPN and age-and morphologically matched controls.
3. There will be significant differences in fall risk between individuals diagnosed with CIPN
and age- and morphologically matched controls.
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Chapter II

REVIEW OF THE LITERATURE
The American Cancer Society (2013) estimated that as of January 1, 2013, there were
13.7 million Americans living with a history of cancer. This number is expected to increase, as it
is estimated that 1,685,210 new cancer cases are expected to be diagnosed in 2013 (Siegel, et al.,
2016). From 1975 to 1977, an individual diagnosed with cancer had a 49% chance of surviving
5 years past his or her initial cancer diagnosis. Today, an individual with a cancer diagnosis has
a 68% chance of surviving at least 5 years past his or her initial diagnosis (Siegel et al., 2016).
Given this increased 5-year relative survival rate, it is of paramount importance to address and
evaluate how a cancer survivor’s quality of life and ability to function are affected by the cancer
treatment process.
Cancer is a general term used for a disease that consists of more than 200 various types
that can occur at any point throughout the lifespan, with different growth rates and abilities to
spread or metastasize, resulting in varying treatment options and prognoses. Despite the
numerous types of cancers, when viewed at the cellular and molecular levels, there are only a
few variations of cancer based upon alterations in genetics and defective cell functions (Eggert,
2010). In global terms, cancer is uncontrolled cell growth and proliferation that develops as a
result of the accumulation of mutations or genetic abnormalities within a cell. Genes can
experience mutations, which cause the cell to increase activity (oncogenes), or mutations, which
result in a decrease in cellular activity (tumor suppressor genes). Regardless of the process, the
result is a nonfunctional cell that will begin to multiply due to its resistance to the normal cell
signaling process. The mutated cells, resistant to apoptosis, which is preprogrammed cell death,
will grow uncontrollably and multiply, forming masses of nonfunctional tissue that will take over
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the space of functional tissue, ultimately causing various malfunctions that disturb normal
processes throughout the body (Pecorino, 2008).
Cancer cells exhibit cellular characteristics that definitively separate them from normal,
healthy cells. A primary characteristic that separates cancer cells from normal cells is that cancer
calls can grow and divide absent of receiving signals from the various environmental and growth
factors that are normally needed for cells to divide. Additionally, unlike normal healthy cells,
cancer cells can ignore growth inhibitory signals. The ability to ignore these signals may be due
to mutations that allow cancer cells to short-circuit the growth factor pathways, resulting in
unchecked and unregulated cell growth (Pecorino, 2008).
Cancer cells can avoid apoptosis, which is preprogrammed cell death. Noncancerous
cells, in response to damage to their DNA or simply as part of the cell cycle, will be destroyed
and removed by apoptosis. However, cancer cells have the ability to evade apoptosis signals and
continue to proliferate (Pecorino, 2008). Cancer cells also possess unlimited replicative
potential. Normal cells contain autonomous counting devices that determine the cell’s finite
replication potential. The counting devices are telomeres, which are located at the ends of
chromosomes. As cells replicate, the telomeres shorten until they reach a length that halts
further replicative processes. However, telomeres of cancer cells are altered and stay a
consistent length despite constant replication, which allows cancer cells to possess unlimited
replicative potential (Pecorino, 2008).
Normal, healthy cells receive oxygen and nutrients from blood vessels. The number and
architecture of these blood vessels remain relatively constant. Cancer cells are able to induce
angiogenesis, which is the creation of new blood vessels. This process is important for cancer
cells as the growth of new blood vessels is needed in order to feed the continuously proliferating
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tumor. Lastly, whereas normal cells will remain in relatively the same location throughout their
life span, cancer cells possess the ability migrate to various other parts of the body, a process
called metastasis (Pecorino, 2008).
Treating cancer can be difficult because not all cancer cells behave in the same manner
(Schneider, Dennehy, & Carter, 2003). Ultimately, the primary goal of cancer therapies, such as
chemotherapy and radiation therapy, are to cause cell death. Traditional cancer treatments
include chemotherapy, radiation therapy, and surgery, which effectively cause cell death
(Navarro & Mejı́a Vázquez, 2010). The goal of these treatments is to achieve and maintain
remission.

Additionally, due to the difficulty in destroying cancer cells, many normal cells are
destroyed in the process, resulting in negative physiological side effects to normal tissues and
body functions (Courneya & Friedenreich, 2011; Schneider et al., 2003). Many of the body
systems, such as the immune system, cardiovascular and pulmonary system, musculoskeletal
system, and gastrointestinal system, will experience extreme toxicities (Courneya &
Friedenreich, 2011; Schneider et al., 2003).
The physiological toxicities to the various bodily system experienced by cancer survivors
may also have negative effects on their psychosocial well-being and quality of life. Many cancer
survivors struggle to cope with physical losses, such as loss of hair or loss of one or both breasts,
the colon, the jaw, or other body part(s). Cancer survivors may experience drastic weight
fluctuations, as well as the development of lymphedema, which is a swelling of an appendage.
Actual or perceived changes in body image may result in anger and/or depression. The extent of
the toxicities and the specific system that is damaged, as well as the extent of the psychological
disturbances that may accompany actual or perceived physical changes, may depend on the
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specific therapy utilized, as well as the intensity of that therapy (Courneya & Friedenreich, 2011;
Schneider et al., 2003).
Chemotherapy is often used in combination with other treatments, such as surgery or
radiation, and is a form of drug therapy that causes cellular death (Airley, 2009). Chemotherapy
may be administered orally or intravenously and is dispersed in repeated courses over a 3- to 6month period. Chemotherapy drugs work by targeting rapidly dividing cells and disrupting the
cells’ ability to replicate. Chemotherapy drugs cannot differentiate between normal, quickly
dividing cells and cancer cells. Consequently, noncancer cells are also destroyed in the process.
For example, hair cells are among those that are rapidly dividing and are often destroyed by
chemotherapy, resulting in loss of hair by the patient. The rapidly dividing cells that comprise
human skin are also affected by chemotherapy drugs, which can routinely produce rashes and
dry skin. The cells that line the inside of human guts and mouths divide at a similar rate as
cancer cells; therefore, chemotherapy typically affects these cells as well, causing various side
effects such as mouth sores, nausea, vomiting, and fatigue (Airley, 2009).
Due to the fact that chemotherapy agents will target normal, rapidly diving cells, patients
undergoing chemotherapy may potentially experience one or more countless side effects. A
common side effect of chemotherapy is chemotherapy-induced peripheral neuropathy (CIPN).
Symptoms of CIPN may be acute, mild or severe, transient or chronic, depending upon
the treatment regime and the dose of the agents. They may manifest in a variety of ways,
involving sensory and motor symptoms (Park et al., 2013; Postma & Heimans, 2000; Wilkes,
2007). Sensory signs and symptoms may include numbness, tingling, burning, pain, ataxia, loss
of deep tendon reflex, and reduced sense of touch, vibration, and proprioception. Motor
symptoms may include weakness, balance disturbances, and difficulty performing fine motor
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skills and a diminished or absent deep tendon reflex. Motor symptoms are less frequent due to
the neurotoxic agent’s inability to cross the blood–brain barrier in concentrations significant
enough to cause harm (Bakitas, 2007; Murillo et al., 2008; Visovsky et al., 2007; Wilkes, 2007).
The autonomic system may also be affected, resulting in constipation, urinary retention, sexual
dysfunction, and altered blood pressure (Bakitas, 2007; Visovsky et al., 2007; Wilkes, 2007).
Sensory changes in the toes and feet are usually first to be noticed, followed by in the
fingers and the hands, progressing in a distal–proximal fashion to the ankles and wrist in a
stocking-glove manner (Park et al., 2013; Wolf et al., 2008). Chemotherapy-induced peripheral
neuropathy symptoms are most commonly distributed in a bilateral and symmetrical pattern. It
is not uncommon for CIPN symptoms to intensify after the neurotoxic agent has been
discontinued; this is referred to as coasting and is the result of cumulating concentrations of the
neurotoxic agent within the body system. In some instances, CIPN symptoms may occur
gradually over a prolonged period. But it is not uncommon for CIPN symptoms to appear
suddenly and intensely (Wilkes, 2007).
The impact of CIPN varies and, thus, affects patients differently. Cumulatively, CIPN
symptoms may negatively alter a patient’s ability to perform routine activities, functions, and
behaviors. Specifically, patients experiencing CIPN symptoms will often report difficulties such
as with sleeping, driving, standing, walking, climbing stairs, balancing, opening containers,
holding onto things, cooking, cleaning, flipping pages of paper, wearing certain shoes and
jewelry, exercising, and socializing (Speck et al., 2011; Tofthagen, 2010). The most common
symptoms reported include burning, muscle aches, and sensitivity to cold (Tofthagen, 2010).
Patients with CIPN reported a variety of symptoms in their feet, including the feelings of “ice
cold,” “walking on hot coals,” or “sandpaper on the bottom of your feet” (Tofthagen, 2010).
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The characteristics of CIPN depend upon the specific chemotherapy agent used, as well
as when the agent is introduced in the treatment protocol and the dosage amount. Induction
chemotherapy is the initial administration of the therapy, the goal of which is to achieve
significant cytoreduction, resulting in complete remission (Airley, 2009).
Consolidation/intensification chemotherapy is administered once remission has been
achieved in order to ensure the disease remains in remission, thus increasing overall patient
survival rates. Adjuvant chemotherapy is administered once the disease has been eradicated by
localized treatment, such as surgery or radiation. Neoadjuvant chemotherapy agents are
administered prior to local therapy to ensure maximal effect of localized therapy. For example,
an agent may be administered to shrink the tumor prior to surgery (Airley, 2009).
Maintenance chemotherapy is administered in lower doses over a prolonged period. This
form of treatment is most often administered in an outpatient or community clinic with the goal
of prolonged remission (Airley, 2009). Salvage chemotherapy is an agent given when all other
treatments have failed, with the purpose of controlling the disease and/or providing palliative
care. Lastly, combination chemotherapy is the administration of a combination of agents, thus
maximizing the effectiveness of the agents to kill the tumor cells throughout various points of the
cell cycle (Airley, 2009).
Although chemotherapy agents will vary in the timing of administration, they also vary in
their chemical composition, resulting in several distinct classes of agents. The incidence of
CIPN and subsequent symptoms depend unto the class of the chemotherapy agent used and the
parts of the nervous system that may be targeted by the various classes of agents (Armstrong et
al., 2005; Wilkes, 2007). Platinum compounds consist of cisplatin, carboplatin, and oxaliplatin.
CIPN has been reported in 57%–92% of cancer patients who received cisplatin (Armstrong et al.,
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2005; Wilkes, 2007). Cisplatin has been known to cause sensory symptoms that progress to a
mixture of sensorimotor symptoms and may also affect the autonomic nerves. The occurrence
depends on the type of platinum analog, total daily dose, and total regimen dose. The risk of
developing CIPN symptoms increases as the cumulative dose reaches 300 mg/m² (Armstrong et
al., 2005; Wilkes, 2007). Research has indicated that cisplatin will affect large axon fibers,
causing axonal swelling, loss of sense of position, and vibration. Cisplatin has been associated
with Lhermitte’s sign, which is a lightning-like sensation that begins in the neck and may extend
posteriorly down the legs during neck flexion. The cause for these symptoms is postulated to be
the result of dorsal column irritation within the spinal cord (Armstrong et al., 2005; Wilkes,
2007). Motor dysfunction is typically seen after sensory loss (Armstrong et al., 2005; Wilkes,
2007). CIPN typically presents late in the treatment or after the treatment has been completed
(Armstrong et al., 2005; Wilkes, 2007).
Oxaliplatin has been shown to cause CIPN symptoms in 82% to 92% of cancer patients
(Armstrong et al., 2005; Wilkes, 2007). It is believed that oxaliplatin will interfere with ion
conductance within the axon, thus affecting the neuron’s ability to become “excited” (Armstrong
et al., 2005; Wilkes, 2007). Oxaliplatin has been associated with two types of neuropathy. The
first is similar to that of cisplatin in that the large fibers are primarily targeted, causing distal
sensory neuropathy. The second type of neuropathy is acute in that it may occur within 30–60
min of the infusion. Cancer patients may develop dysesthesias of the hands and feet, jaw
tightness, and a sensation of loss of breath (Armstrong et al., 2005; Wilkes, 2007). Acute
neuropathy symptoms have been reported to be exacerbated by exposure to the cold, as well as
the dose and infusion time of a particular agent. The risk for developing symptoms increases as
the cumulative dose reaches 750 to 800 mg/m² (Armstrong et al., 2005; Wilkes, 2007).
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A recent prospective study investigated the incidence and severity of acute oxaliplatininduced peripheral neuropathy in 170 patients diagnosed with metastatic colorectal cancer. The
patients, who had a mean age of 63.7 years, received either a combination of leucovorin, 5fluoruracil, and oxaliplatin, or a combination of capecitabine and oxaliplatin. The National
Cancer Institute’s Common Toxicity Criteria were used to assess severity of accumulation
oxaliplatin sensory and motor neuropathy symptoms. Sensory and motor nerve conduction
studies were performed on the ulnar, radial, peroneal, and sural nerves and were repeated after
six courses (oxaliplatin planned dose, 510 mg/m²) and 12 courses (oxaliplatin planned dose,
1,020 mg/m²) of the cepecitabine regiments and after four courses (oxaliplatin dose, 520 mg/m²)
and eight courses (oxaliplatin dose, 1,040 mg/m²; Argyriou et al., 2013).
Argyriou and colleagues (2013) found that 85.9% of the patients experienced acute
oxaliplatin-induced peripheral neuropathy and 72.4% of patients experienced chronic oxaliplatininduced peripheral neuropathy with the worst symptoms associated with the cumulative dosages
of oxaliplatin (Spearman rho = 0.171; p = .026). The incidence of acute oxaliplatin-induced
peripheral neuropathy was also significantly correlated with the incidence (r = 0.601; p < .001)
and severity (r = 0.702; p < .001) of chronic oxaliplatin-induced peripheral neuropathy.
Argyriou and colleagues (2013) also noted that sensory action potentials in all three sensory
nerves experienced deterioration. Thus, the results of the study suggest that oxaliplatin may
induce acute and chronic peripheral neuropathy, which was accompanied by amplitude
deterioration of sensory action potentials, which was linked to chronic neuropathy (Argyriou et
al., 2013). The conclusion reached by Argyriou and colleagues (2013) is consistent with
previous research, which has shown oxaliplatin to cause sensory peripheral neuropathy
accompanied by changes in nerve conduction velocities.
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Taxanes, which are plant-derived poisons, include paclitaxel and docetaxel, and will
often cause microtubular aggregation (Armstrong et al., 2005; Wilkes, 2007). Chemotherapyinduced peripheral neuropathy associated with pacelitaxel and docetaxel depends on the agent
used, administration schedule, cumulative dose, and whether or not it is combined with another
agent (Armstrong et al., 2005; Wilkes, 2007). It has been reported that 59% to 78% of patients
who receive doses of at least 200 mg/m² and up to a cumulative dose of 1,400 mg/m² of
paclitaxel may experience neuropathy that is mild to moderate in nature (Armstrong et al., 2005;
Wilkes, 2007). Peripheral neuropathy symptoms associated with docetaxel, which occur in 20%
to 58% of cancer patients, are usually not present until the cumulative dose exceeds 600 mg/m².
Docetaxel has been known to cause damage to small fibers, resulting in sensorimotor symptoms
(Armstrong et al., 2005; Wilkes, 2007).
The incidence of taxane-induced peripheral neuropathy is contingent on various factors,
such as the treatment schedule, single dose per course, and cumulative dose. Other factors, such
as prior or simultaneous administration of platinum compounds or vinca alkaloids, age,
preexisting peripheral neuropathy due to other medical conditions, such as hereditary ones
associated with nutritional agents, paraneoplastic, diabetes mellitus, and alcohol abuse. It is
suggested that when patients receive a combination of paclitaxel plus cisplatin or paclitaxel plus
carboplatin, peripheral neuropathy may present as axonal, predominately sensory peripheral
neuropathy that is mild to severe. Patients who receive paclitaxel plus cisplatin may experience
peripheral neuropathy 69.2% of the time, whereas patients who receive paclitaxel plus
carboplatin may experience peripheral neuropathy 66.6% of the time (Argyriou, Koltzenburg,
Polychronopoulos, Papapetropoulos, & Kalofonos, 2008).
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Vinca alkaloids, which consist of vincristine, vindesine, and vinblastine, have been
associated with peripheral neuropathy. Vincristine has been associated with the greatest effects
(Armstrong et al., 2005; Wilkes, 2007). Vincristine has been shown to cause peripheral
neuropathy in 57% of cancer patients when the cumulative dose exceeds 6 mg/m². Vincristine,
which may cause aggregation of microtubules, thus causing degeneration and atrophy of
peripheral nerve fibers, may cause the symptoms of pain and temperature sensation (Armstrong
et al., 2005; Wilkes, 2007).
The chemotherapy agent bortezomib has been shown to cause CIPN symptoms in 35% of
patients. The symptoms are most often sensory in nature and rarely involve motor deficits.
Thalidomide has been associated with CIPN symptoms in 25% to 81% of patients. Lastly,
thalidomide predominantly causes sensory symptoms, with the risk of symptom development
increasing as the cumulative dose exceeds 400 mg/m² (Armstrong et al., 2005; Wilkes, 2007).
Although all cancer cells have six common characteristics, there are over 200 different
types of cancer. The heterogeneity of cancer is reflected in the various treatment types.
Chemotherapy is a general term for a variety of classes of drugs that may be administered alone
or in combination with other treatments, as well as at various times throughout the cancer
journey. Despite the numerous types of chemotherapy agents, a common side effect is
chemotherapy-induced peripheral neuropathy.
Pathophysiology of Chemotherapy Induced Peripheral Neuropathy
The symptoms patients experience are due to the neurotoxic effects chemotherapy agents
have on the peripheral nervous system. Briefly, the nervous system has two main components:
the central nervous system (CNS) and the peripheral nervous system (PNS). The central nervous
system consists of the brain and spinal cord. The human system is continuously immersed with
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sensory information from a variety of sources from the environment, as well as from movement,
touch, awareness of the body in space, sight, sound, and smell. During high-order motor
behaviors, such as walking, the brain and central nervous system (CNS) must correlate the
various sensory inputs with motor outputs in order to control the body as it moves and interacts
with the environment (O’Sullivan & Schmitz, 2007). The CNS will use this information to
modulate movement by both feedback and feedforward control. Feedback control occurs during
movement, in which sensory information is used to monitor and adjust active movement.
Feedforward control is proactive and utilizes sensory information that has been learned through
previous experience to send signals prior to the movement to allow anticipatory postural
adjustments to be made to control posture or movement. Thus, sensory information plays critical
roles in movement in that sensory information will aid in the selection of proper motor actions in
response to the environment and adapt and shape motor programs through feedback, allowing for
corrective actions to occur in response to a dynamic environment (O’Sullivan & Schmitz, 2007).
The main task of the PNS is to convey signals of information, such as sense of touch,
pain, temperature, position, and vibration sense, from the periphery to the CNS. The
responsibility for signal transmission belongs to the neuron, which is the basic component of the
nervous system and is composed of three distinct structures: the cell body, the dendrites, and the
axon (Magill, 2013). The neuron generates electrical signals from one part of a cell to another
part of the same cell or a neighboring cell. For most neurons, this electrical signal will cause the
release of neurotransmitters, which are chemical messengers that allow cells to communicate
with one another (Cuccurullo, 2010). Each neuron has a cell body (or stoma) within which the
cell’s nucleus and ribosomes reside. Branching out from the cell body are dendrites, which are
responsible for receiving signals from other cells. The long extension from the cell body is
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called the axon, and may also be referred to as the nerve fiber (Cuccurullo, 2010). The axon
extends from the cell body and carries the output signal to other cells. The axon can vary in
length, ranging from a few microns to over a meter (Cuccurullo, 2010).
Neurons are classified according to their function. A neuron may either receive or send
information by a neural impulse. A signal may be sent to, from, or within the central nervous
system, which is composed of the brain and spinal cord. Neurons have three functional classes,
which include sensory neurons (also called afferent neurons), motor neurons (also called efferent
neurons), and interneurons, which originate and terminate in the brain or spinal cord, acting as
connections between axons descending within the brain or spinal cord (Magill & Anderson,
2013). Sensory neurons send neural impulses to the central nervous system (CNS), whereas
motor neurons send neural impulses from the CNS to skeletal muscle fibers (Magill & Anderson,
2013).
The PNS is composed of afferent and efferent divisions. The afferent neurons will
transmit information from sensors located in the periphery to the CNS, whereas the efferent
neurons will transmit signals from the CNS to muscles or glands (Widmaier, Raff, & Strang,
2006). The peripheral nervous system has three functional divisions, which are the sensory
nerves, motor nerves, and the autonomic nerves. The sensory nerves sense touch, pain,
temperature, position, and vibration sense. The motor nerves are responsible for voluntary
movement, muscle tone, and coordination. The autonomic nerves are responsible for the control
of intestinal motility, blood pressure, and involuntary muscles (Widmaier et al., 2006).
Anatomically, the afferent nerves of the peripheral nervous system are composed of small
and large fibers. The small fibers are unmyelinated and consist of nerves that sense pain and
temperature. The large nerve fibers are myelinated and consist of nerves that sense position and
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vibration, as well as motor control (Armstrong et al., 2005). The small nerve fibers are primarily
composed of microtubules, which transport proteins throughout the nerve fiber. Large nerve
fibers are primarily composed of neurofilaments, which comprise the axon’s framework. Sensory
nerves terminate at the level of the skin and extend to the dorsal root ganglion, connecting with
either the dorsal column via a large fiber or the spinothalamic tract via a small fiber in the spinal
cord (Armstrong et al., 2005).
The somatosensory system, which consists of muscle spindles, Golgi tendon organs, joint
receptors, and cutaneous receptors, contributes to the modulation of spinal pattern generators,
modulation of motor commands, and perception and control of movement through sensory
information. Specifically, there are several different types of receptors at the end of the afferent
nerves, which provide information with regard to length and tension in muscles and tendons,
sense of joint positions, as well as heat, cold, touch, pressure, and skin of body parts affected by
the action of muscles.
Collectively, these distinct receptors and their afferent nerves, which may be referred to
as the somatosensory system, provide the CNS information with respect to muscle length and
tension, movement of the joints, the effect of movement on the overlying skin, as well how the
body is interacting with the external environment. The CNS will interpret this information and
send a command via efferent nerves to implement an action (Widmaier et al., 2006). These
sensory neurons will provide information about mechanical stimuli, temperature changes,
potential damage to the skin, body and limb movement and position, as well as velocity and
muscle activation (Magill & Anderson, 2013; Shumway-Cook & Woollacott, 2012). Of
particular interest may be cutaneous receptors, which consist of mechanoreceptors,
thermoreceptors, and nociceptors, which are located within sensitive areas of the skin, with as
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many as 25,000 per square centimeter (Shumway-Cook & Woollacott, 2012). Cutaneous
sensory receptors provide information about the body’s orientation within the immediate
environment and provide information necessary for reflexive responses. Cumulatively, sensory
receptors within the somatosensory system provide information by afferent nerve fibers to the
spinal cord, which allows for the modulation of locomotion.
The neurotoxic effects of chemotherapy agents on the peripheral nervous system are
wide-ranging, targeting many components of the peripheral nervous system, such as the axons
and cell bodies of dorsal root ganglion neurons, and resulting in axonal damage, which is
characterized by a decrease in intraepidermal nerve fiber density and terminal arbor degeneration
(Han & Smith, 2013). Chemotherapy agents will also exert their toxicity on mitochondria,
causing them to become swollen and vacuoled, as well as create oxidative stress, causing
inflammation. Pathologically, the dorsal root ganglion neurons and surrounding satellite cells
may negatively alter the expression of various ion channels, neurotransmitters, and receptors, as
well as exhibit altered gene expression. The mitochondrial dysfunction and IENF loss seem to
be directly correlated to the presence of pain. Cumulatively, these changes cause various sensory
symptoms, such numbness, tingling, burning, pain, and reduced sense of touch, as well as motor
symptoms, such as may include weakness, balance disturbances, and difficulty performing fine
motor skills, which are frequently reported by cancer patients undergoing chemotherapy
treatment (Bakitas, 2007; Han & Smith, 2013; Murillo et al., 2008; Park et al, 2013; Visovsky et
al., 2007; Wilkes, 2007).
Although there is a wide range of neuronal targets for various chemotherapy agents, it is
estimated that platinum drugs (antineoplastic agents), such as cisplatin and oxaliplatin, may
generally target the DRG and ion channels. Oxaliplatin may cause an acute peripheral
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neuropathy by causing the nodal axonal voltage-gated sodium and calcium channels to become
dysfunctional (Argyriou, Bruna, Marmiroli, & Cavaletti, 2012). In animal models, rats treated
with oxaliplatin did not experience degeneration of peripheral nerve axons (A-fibers and Cfibers), but there was a partial loss of intraepidermal nerve fibers, which was accompanied by a
reduction in sensory nerve conduction velocity that lasted well after the cessation of treatment,
suggesting deficits may be chronic rather than acute. There was no reduction in motor nerve
conduction velocity. The rats treated with oxaliplatin also experienced slower and more irregular
and spontaneous discharges patterns in A-fibers and C-fibers, swollen and vacuolated
mitochondria, and mechano-allodynia, mehcano-hyperalgesia, and cold-allodynia, which is
consistent with patient-reported symptoms (Xiao, Zheng, & Bennett, 2012). It has also been
proposed that platinum compounds will alter the tertiary structure of DNA by forming
intrastrand adducts and interstrand crosslinks, thus inducing apoptosis and causing neuronal
apoptosis through oxidative stress and mitochondrial dysfunction (Argyriou et al., 2012).
Taxanes, such as paclitaxel and docetaxel, are thought to disturb the function of the
microtubules of the mitotic spindle, thus negatively affecting axonal transport, which may evoke
the typical “dying-back” pattern. Taxanes will also evoke certain cellular processes, such as
macrophage activation in both the DRG and peripheral nerve, as well as microglial activation
within the spinal cord, which has been postulated to contribute to the development of taxaneinduced peripheral neuropathy. Recent studies suggest that paclitaxel may cause the axonal
microtubules to undergo a massive polar reconfiguration, which is often accompanied by
impaired organelle transport, resulting in degeneration of intraepidermal terminal arbors of
primary afferent neurons, and is associated with increased incidence of swollen and vacuolated
axonal mitochondria in A-fibers and C-fibers (Argyriou et al., 2012). Furthermore, paclitaxel
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and docetaxel can induce a ganglionopathy that attacks the cell bodies, particularly those of the
dorsal root ganglia (DRG), or myelinopathy with primary segmental demyelination. Taxanes
have been known to affect sensory neurons, especially myelinated nerve fibers of vibration
sensation and proprioception. Nerve biopsies have shown that taxane-induced peripheral
neuropath are mostly ganglionopathic in nature, rather than axonopathic (Argyriou et al., 2008).
Taxane-induced peripheral neuropathy may most often present a sensory neuropathy,
although motor neuropathy is not uncommon. The primary affected fibers are the thick
myelinated nerve fibers conducting sensation and sense of position. Symptoms may also include
loss of pain and temperature sensation and loss of tendon reflexes (Argyriou et al., 2008).
Electrophysiological abnormalities include decrease or loss of sensory response, slower motor
conduction velocities, or F-wave latency delay, suggesting primary demyelination, as well as the
possibility that damage has also occurred to the myelin-Schwann cells. Secondary
demyelination may also occur, which consists of minor increases in distal latency and decreased
conduction velocity (Argyriou et al., 2008). It has also been noted that sural nerves may
experience reduced or loss sensory nerve potentials velocity (Argyriou et al., 2008).
While taxanes may produce a symmetric, axonal neuropathy that is predominately
sensory in nature, motor neuropathy may occur but is often difficult to recognize because of the
very mild weakness that occurs in muscles. However, when motor neuropathy does occur,
reduction occurs in the compound muscles action potential response that can be noted, which
indicates axonal loss, highlighted by electromyography (EMG), showing active denervation
changes in the distal muscles of the lower limb velocity (Argyriou et al., 2008).
Two to 3 days after paclitaxel treatment, myopathy with proximal weakness and
myopathic EMG changes are known to occur. High doses of taxanes have been known to cause
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severe myalgia, particularly in the shoulder and paraspinal muscles. Biopsies of nerves
subjected to taxanes have shown nerves to experience axonal degeneration and have reduced
myelinated nerve fiber density and loss of large-fiber velocity (Argyriou et al., 2008). However,
recent research using in vivo chronic animal models of CIPN in female Wistar rats what were
administered cisplatin, paclitaxel, or a combination of both, found that while there was a
decrease in nerve conduction velocity, there was no change in myelin structure (Gilardini, 2012).
Thus, the exact pathophysiology of CIPN remains unknown at this time.
The risk for developing CIPN can be further increased in individuals who have been
previously been diagnosed with diabetes, alcohol-related peripheral neuropathy, ischemic
disease, vitamin deficiencies, renal insufficiency, prior exposure, or concurrent use of neurotoxic
agents (Armstrong et al., 2005; Wilkes, 2007). Additionally, the incidence and severity of CIPN
depends upon the intensity and duration of a single dose, as well as the total number of doses and
any prior or concurrent doses. Furthermore, any prior or concurrent exposure to cisplatin may
increase the incidence and severity of CIPN. A medical history of diabetes and alcohol abuse
can also affect the incidence and severity of CIPN (Jaggi & Singh, 2012). Although CIPN may
reverse itself once the agent has been stopped, many times CIPN symptoms may be irreversible
(Wilkes, 2007).
Due to the neurotoxic effect of chemotherapy agents, the CNS may not receive vital
information. As such researchers have begun investigating the effects of chemotherapy agents
on the somatosensory system. Visovsky and Daly (2004) evaluated the change in CIPN
symptoms within cancer survivors undergoing chemotherapy. To evaluate the presentation of
CIPN and changes in nerve function, Visovsky and Daly evaluated the vision, hearing, deep
tendon reflexes, vibratory sense, cutaneous sensation, gait, balance, muscle strength, and
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orthostatic blood pressure of cancer survivors undergoing chemotherapy. Measures were
assessed at baseline, which was before the participants started receiving chemotherapy. The
participants were reassessed at 4 weeks and 12 weeks into treatment. Gait and balance were
assessed using portions of the Tinetti Performance-Oriented Assessment of Balance and Gait
instrument, which requires the participant to display mobility and balance throughout a series of
maneuvers. The investigators observed gain initiation, step height, step length, step symmetry,
step continuity, path deviation, trunk stability, walk stance, and turning while walking. The test
is a valid and reliable measure that focuses on maintenance of position, postural responses to
voluntary movement, and perturbation and gait mobility. The test is simple to administer;
however, the scoring criteria are vague. Thus, it is difficult to detect small changes in
spatiotemporal gait parameters (O’Sullivan & Schmitz, 2007). Visovsky and Daly (2004) also
assessed deep tendon reflexes using Babinski’s reflex hammer, vibratory sense using a tuning
fork, cutaneous sensation using Semmes-Weinstein monofilaments, and muscle strength using a
handheld dynamometer (Visovsky & Daly, 2004).
Visovsky and Daly (2004) observed changes in vision, hearing, deep tendon reflexes,
vibratory sense, cutaneous sensation, balance, muscle strength, and orthostatic pressure; gait
remained unchanged. Although the changes in outcomes may not have been statistically
significant, Visovsky and Daly noted that this may be due to the small, homogenous sample size.
Furthermore, an interesting finding in the present study was that the participants experienced an
18% decline in dynamic balance but no changes in gait. This discrepancy may by a function of
the tool, as the Tinetti Performance-Oriented Assessment of Balance and Gait instrument uses a
vague scoring criterion and thus cannot detect small changes in spatiotemporal gait parameters.
However, the Tinetti Performance-Oriented Assessment of Balance and Gait may not have been
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the best tool to use, as a recent study suggested that to assess risk of falls for those with
neuropathy, either the Functional Reach test, Timed Up and Go test, the Berg Balance Scale, or
the Dynamic Gait Index may be more appropriate (Jernigan, Pohl, Mahnken, & Kluding, 2012).
More specifically, Jernigan and colleagues (2012) suggested that in the clinical setting sensitivity
is the most important measure because high sensitivity corresponds to more true positives and
fewer false negatives. Thus, the Timed Up and Go test may be a better test to asses fall risk due
to its high sensitivity of 90% and high diagnostic accuracy at 88.9%. Furthermore, Visovsky and
Daly stated the data may have been more accurately and consistently captured had a highly
trained examiner performed the data collection. The examiners in this study are experienced
nurse practitioners; thus, their lack of expertise on the clinical measures may have resulted in
inherent intrasubject variability. However, the results of the current study suggested a trending
decline in peripheral nerve function through treatment and the current clinical outcomes used,
thus warranting further investigation.
Lastly, an interesting finding in the present study was that participants experienced an
18% decline in dynamic balance, as well as a reporting of recurrent falls, which are significant
events, especially in the older population, as falls have been linked to serious injuries and
disabilities, loss of independence, fear of falling, and increased mortality rates (Kelsey, ProcterGray, Hannan, & Wenjun, 2012; Visovsky & Daly, 2004).
Hilkens, Verweij, Vecht, Stoter, and van den Bent (1997) conducted a series of case
reports of cancer survivors undergoing chemotherapy treatment with docetaxel, a taxane-based
agent. Common symptoms experienced throughout the case reports were sensory signs and
symptoms that started with paresthesia and numbness in the hands and feet. The case reports
insinuated a loss of tendon reflexes and vibratory perception, along with disabling pain, which
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suggested involvement of small, unmyelinated nerve fibers. In conjunction with patient-reported
numbness and paresthesia, several of the patients reported a loss of dexterity and an increasingly
unsteady gait (Hilkens et al., 1997).
Hile, Fitzgerald, and Studenski (2010) conducted a case study to investigate the severity
and impact of neurotoxic chemotherapy on one individual. The individual being studied was
diagnosed with breast cancer and received paclitaxel after undergoing a curative mastectomy.
Before the patient began taxane chemotherapy, baseline testing was administered, which
consisted of the Short Physical Performance Battery and quantified standing, walking, and
repeated chair stands. The patient’s baseline testing indicated an active woman with no
functional deficits of neuropathic symptoms. However, after three cycles of paclitaxel therapy
over the course of 12 weeks, the patient experienced a 50% decline in her performance-based
measures. The patient now required a cane for walking as her gait became unsteady and
decreased by 0.46 m/s. Additionally, at 12 weeks, the patient scored 1/4 for balance (3.6 s
semitandem), 3/4 for gait (0.74 s), and 1/4 for chair stands (16.9 s), as well as reported
difficulties in performing mobility-related tasks and a higher incidence of falls. Furthermore,
testing revealed a significant decrease in balance (Hile et al., 2010). The results of this case
study suggested that chemotherapy may have a deleterious impact on physical function. Even
more important is the reporting of recurrent falls, which are significant events, especially in the
older population, as falls have been linked to serious injuries and disabilities, loss of
independence, fear of falling, and increased mortality rates (Kelsey et al., 2012). Therefore,
research suggested that certain chemotherapy agents may negatively affect proprioception and
sensory feedback, thus impairing certain aspects of function and mobility.
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In summary, chemotherapy-induced peripheral neuropathy is characterized by multiple
sensory changes, which include mechanical allodynia, cold allodynia, slowing of sensor nerve
conduction velocity, and loss of heat sensitivity. Although the exact pathophysiology of CIPN
remains unclear, research suggested decreases in intraepidermal nerve fiber density and terminal
arbor degeneration, which are associated with mitochondrial dysfunction, mitotoxicity, and
oxidative stress (Han & Smith, 2013). Cumulatively, CIPN causes a host of uncomfortable and
painful sensations throughout the periphery of a cancer patient’s extremities.
In addition to the unconformable and often painful sensory nature of chemotherapyinduced peripheral neuropathy, CIPN may also cause a loss of peripheral sensation,
proprioception, and lower-extremity muscle weakness, which may interfere with balance and
gait (Tofthagen et al., 2012).
Motor activity, such as gait, is the result of the integration of neuronal signal of the motor
control systems within the central and peripheral nervous system (Shumway-Cook & Woollacott,
2012). Motor control may be defined as the “ability to regulate or direct the mechanisms
essential to movement” (Shumway-Cook & Woollacott, 2012, p. 3). Movement is the result of
three factors and their interactions with one another. These three factors are the individual, the
task, and the environment (Shumway-Cook & Woollacott, 2012).
Although there may be just three factors that interact to produce movement, the way in
which these three factors interact is complex, resulting in multiple theories of motor control and
how movement is controlled. The first of the two leading theories is related to motor programs,
or the central pattern generator (CPG), which is a neural circuit of networks that generate
rhythmic motor patterns without the influence of sensory or descending inputs (Kelso, 1995). A
central pattern generator (CPG) is a genetically defined (inherited) central organization located
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within the brain stem or spinal cord. It is theorized that there are specific patters of motions,
such as for walking and swimming, and that these patterns may be multifunctional, producing
several variations within a movement. For example, during gait, one may walk, run, skip, hop,
bound, or jump (Kelso, 1995).
According to the motor program theory, a set of commands defines and shapes an action,
which is then modified by sensory information. A stimulus (a command neuron) will trigger and
initiate the CPG’s action in the brain. The CPG will then send rhythmic, oscillating instructions
to the musculature. These signals (instructions) create limb movement that are often
characterized as reciprocal and repetitive in nature (MacKay-Lyons, 2002).
Although research indicates that CPGs are primary contributors to motor control, sensory
and reflexive processes are needed in order to modify these commands to allow for adaptations
to the changing environment; thus, central pattern generators are not the sole determinants of a
movement (Shumway-Cook & Woollacott, 2012). Premovement information, such as posture
and body orientation, are used by individuals to prepare for movement, as well as various reflex
mechanisms, which will aid in the generation of rapid connections in order to successfully
perform an action in dynamic environments (Schmidt & Wrisberg, 2008). In this theory, the
brain stem controls both the CPG and the reflexes that mediate the afferent inputs to the spinal
cord. The spinal reflex pathways and descending pathways merge information within a common
spinal interneuron to integrate various information (Dietz, 2002). The supraspinal descending
tracts provide inputs that help shape the output patterns of CPGs. The mesencephalic locomotor
region (brain stem) transmits information to the flexors and extensor neurons during flexion and
extension muscle activations throughout the gait cycle. The descending tracts also aid in the
stabilization of gait rhythms (MacKay-Lyons, 2002).
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The second of the two leading theories is systems theory, which states that in order to
understand the neural control of movement, one must understand the system’s characteristics in
which the movement occurs, as well as the external and internal forces that are acting on the
body (Bernstein, 1967). Bernstein (1967) studied the body as a whole mechanical system that
has mass and is subject to external forces, such as gravity, and internal forces, such as inertial
and movement-dependent forces. Bernstein suggested that even though two central commands
may be equal, the two resulting movements may be quite different due to the interplay between
external forces and variations within initial conditions. Bernstein also suggested that many
interacting systems play a role in movement integration (Bernstein, 1967). Bernstein put forth
the idea that the body, as a mechanical system, has multiple degrees of freedom that must be
controlled during movement. For example, the body contains numerous joints that can flex,
extend, and sometimes rotate, which will complicate movement. Bernstein hypothesized that
control of the various degrees of freedom is hierarchical in nature in that the higher portions of
the nervous system will control the lower portions of the nervous system, which in turn will
activate synergies, or groups of muscles, that act as a unit (Shumway-Cook & Woollacott, 2012).
Over the years, Bernstein’s system theory has evolved into the dynamical systems theory,
which states that when the individual parts of a system are combined, the individual elements
will start to behave collectively, resulting in an ordered way (Shumway-Cook & Woollacott,
2012). When applied to motor control, dynamical systems theory may predict movement based
on the elements involved and their interactions, ignoring any specific commands or motor
programs of the nervous system (Shumway-Cook & Woollacott, 2012). Dynamical systems
theory states that a new behavior pattern will occur when there is a change in the system, called
the “control parameter.” A control parameter is a variable that alters a system’s behavior. For
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example, as an animal’s walking velocity increases, it will reach a certain velocity that dictates
the animal’s behavioral change from a walk to a trot (Shumway-Cook & Woollacott, 2012).
This is in stark contrast to the theory of central pattern generators, as the dynamical system
deemphasizes the existence of central nervous system commands (Shumway-Cook &
Woollacott, 2012).
A key concept in dynamical systems theory is that of variability and its role in movement
control (Shumway-Cook & Woollacott, 2012). Dynamical systems theory states that human
movement functions optimally due to its inherent variability, which may consist of the variations
that normally occur during motor performance throughout multiple task repetitions. In the
central pattern generator theory, variability is the result of errors that occur during motor
performance and assumes that these errors can be reduced through skill acquisition, which results
in decreases in variability and error (Shumway-Cook & Woollacott, 2012). On the other hand,
dynamical systems theory views variability as positive, as it allows for flexible and adaptive
strategies to occur as the environment changes, which is essential for normal movement to occur.
In this theory, a lack of variability may result in injury, whereas excessive variability results in
movement impairments, such as with persons with ataxia (Shumway-Cook & Woollacott, 2012).
Thus, dynamical systems theory views a small amount of variability as positive because it
indicates highly stable and preferred movement patterns, which is called an attractor state. An
example of an attractor state with walking is a person walking at various speeds who, barring
outside influences, will walk at a preferred state that is the most energetically efficient
(Shumway-Cook & Woollacott, 2012).
The dynamical systems theory does have its limitations. Although this theory does take
into consideration all of the contributors to movement, such as muscles and skeletal systems, as

EFFECTS OF CIPN ON GAIT AND FALL RISK

45

well as gravity and inertia, it does minimize the role of the nervous system. The dynamical
system states that the nervous system in isolation does not predict movement, which is contrary
to central pattern generator theory (Shumway-Cook & Woollacott, 2012).
Despite these differences, both theories of motor control must incorporate the basic
systems of control: open-loop and closed-loop control systems. The primary difference between
these two systems is that a closed-loop system involves feedback, whereas an open-loop system
does not. In human movement, such as walking, the feedback is afferent information sent by
various sensory receptors to the control center, which will provide modulation of movement
while it is in progress (Magill & Anderson, 2013).
Regardless of the theory, movement depends on the coordinated integration of the
individual, the task, and the environment. From the CPG perspective, movement is the result of
a central command that sends signals via inherent neural networks. From the dynamical system
theory (DST) perspective, movement is based on the elements involved and their interactions,
ignoring any specific commands. Furthermore, although the origin of movement may be very
different between these two theories, both CPG and DST rely on peripheral sensory information
and joint receptor and muscle spindle information sent via afferent pathways for the modulation
of locomotion. Previous research using animal subjects has shown that when sensory nerves are
cut (deafferented), commands can still be processed and locomotion is generated. However, the
resulting locomotion is unmodulated and often sloppy and uncoordinated. Research has shown
that, even though CPGs allow for locomotion to occur in the absence of proprioception, afferent
feedback is a prime contributor in the generation of stable and modulated movement (MacKayLyons, 2002). Specifically, afferent feedback provides position sense, direction, and force
movement, resulting in rhythmic movements (MacKay-Lyons, 2002).
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Whereas a central pattern general (CPG) may provide a movement command, load
receptors in the muscles and tendons provide important information that allows for a smooth gait
pattern. For instance, load receptors located in the tibias anterior provide information to the CNS
that aids in the regulation of the activation time and duration for the gastrocnemius. Receptors in
the hip provide afferent formation that is critical during phase transitions for different movement
patterns (Dietz, 2002).
Thus, sensory information plays a critical role in movement in that sensory information
will aid in the selection of proper motor actions in response to the environment and adapt and
shape motor programs through feedback, allowing for corrective actions to occur in response to a
dynamic environment (O’Sullivan & Schmitz, 2007). Sensory feedback control plays a critical
role in adjusting stride-to-stride limb trajectories in order to smooth out irregularities during
unperturbed movements and safely navigate and maintain balance (Gandevia & Burke, 1992).
Sensory information and information provided by Golgi tendon organs and muscle spindles
provide critical information for the generation of rhythmic alternating contractions in muscles,
indicating that sensory information plays a role in locomotion. Specifically, sensory information
contributes to stepping frequency. Furthermore, joint receptors and the muscle spindle afferent
(from stretch hip flexors) contribute to the regulation of phase transitions and timing of when the
legs should swing forward, thus contributing to the rhythm of gait (Dietz & Duysens, 2000;
Shumway-Cook & Woollacott, 2012).
Sensory information and proprioceptive information are also critical for the regulation
and control of one’s body position through locomotion. The ability to maintain postural stability
during locomotion is a key and fundamental task. Postural control, which may be defined as the
ability to control one’s body position in space, and maintaining an appropriate relationship
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between one’s body segments and between the body and the environment for a task are critical in
order to keep the body stable and oriented. Postural stability, also known as balance, is the
ability to control the center of mass in relationship to the base of support. The center of mass is
defined as a point that is at the center of the total body mass (Shumway-Cook & Woollacott,
2012). The base of support is defined as the area of the body that is in contact with the support
surface. Previous research indicates that the central nervous system will control the body’s
center of mass in order to maintain postural control. Another term and concept critical to
postural control is center of pressure. The body will generate forces in order to control the
motion of the center of mass. The center of pressure is the center of the distribution of the total
forces applied to the supporting surfaces. The center of pressure moves continuously around the
center of mass to keep it within the base of support (Shumway-Cook & Woollacott, 2012).
Every task requires an orientation component and stability component, and these
requirements will change depending upon the task and the environment. During locomotion,
postural control ensuring orientation and stability is essential. During gait, the body’s center of
mass (center of gravity) does not stay within the base of support of the feet; thus, the body is in a
constant state of imbalance. However, individuals do not always fall while walking because
normally the foot that swings forward during gait is placed ahead of and lateral to the center of
gravity as it moves forward, keeping the center of mass relative to the moving base of support
(Shumway-Cook & Woollacott, 2012).
Therefore, there are several neural components that are critical for postural control, such
as motor processes, which are the organization of muscles to perform actions such as swinging
the leg forward; sensory/perceptual processes, which consist of organizing and integrating
various visual, vestibular, and somatosensory systems; and lastly high-level cognitive processes
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for interpreting the information provided by the sensory and perceptual process in order to
produce an appropriate action. According to dynamical systems theory, postural control is due to
the complex interactions of various body systems working cooperatively to control the body’s
orientation and stability (Shumway-Cook & Woollacott, 2012).
Thus, the generation, maintenance, and regulation of gait requires input from specific
neuronal mechanisms, such as afferent feedback and proprioceptive information and neuronal
circuits in the spinal cord, thus shaping a movement pattern. There are three reflex systems that
contribute to the modulation of gait: the monosynaptic reflex, which is mediated by Ia afferent
nerves; the cutaneous reflexes, which is mediated by the skin afferents; and the polysynaptic
reflexes, which integrate afferent inputs from a variety of sources (Dietz, 2002).
The monosynaptic reflex, also known as the spinal stretch reflexes or myotatic reflex, is a
preprogrammed response by the body due to a stretch stimulus in the muscle. When a muscle
spindle is stretched, the spinal cord receives a signal immediately and responds by having that
muscle contract. The myotatic reflex is critical for posture and gait because if the body begins to
deviate due to an obstacle or change in terrain, the stretch reflex will quickly counter interruption
and ensure the body’s center of mass is over the base of support. Furthermore, during gait, this
reflex, such as the H-reflex of the soleus, may provide compensation for irregularities in the
ground. However, it still remains unclear as to the magnitude of the functional impact the stretch
reflex has during gait. The monsynaptic reflex system is very sensitive to small inputs, thus only
responding to small irregularities on the ground. So, the afferent input that is selected in
response to what is occurring in the body’s external environment is critical because the neuronal
signals of the muscle stretch or length is not enough to control the body during gait. Body
control requires a combination of afferent inputs (Dietz, 2002).
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The second reflex system is the cutaneous system. Muscles will respond to sensory
nerves that are induced by electrical stimuli. Various limb muscles will have this response
mechanism that has a latency similar to that of spinal pathways. Cutaneous leg muscle reflexes
are motor task specific, providing profound modulation that depends on the context in which
they are evoked. Cutaneous leg reflexes are also nerve specific, which appears to be important
for function, and may include central pattern generators (Dietz, 2002).
Lastly, polysynaptic reflexes are mediated by muscle proprioceptive input from group 2
afferent fibers, which are static muscle spindles or skin. From a functional perspective,
polysynaptic reflexes may be particularly important for function because they may provide
compensatory responses during gait that are more complex than simple stretch–reflex responses.
The polysynaptic pathway integrates inputs from muscle, joint, and cutaneous afferents, and
combines these inputs with commands from supraspinal centers to common spinal interneurons.
The polysynaptic reflex has both excitatory and inhibitory connections for both extensors and
flexors. The polysynaptic reflex sensory input determines direction, velocity, and amplitude of
the bodily adjustments through specific patterns of leg muscle activation needed by individuals
to maintain their center of gravity over their feet (Dietz, 2002).
Afferent information for locomotion will be provided from a variety of sources. In
addition to receptions in the skin and muscles, afferent information will be provided from visual
and vestibular sources. Spinal reflex pathways and descending pathways will converge on a
common interneuron in which these inputs will be integrated. For examples, activity from the
length sensors in muscles (i.e., the muscle spindles) will be reduced by visual feedforward
information. Additionally, proprioceptor information from the leg muscles during gait may
determine the amount and degree of influence of vestibulospinal input to stabilize the body

EFFECTS OF CIPN ON GAIT AND FALL RISK

50

during movement. On the other hand, the amount and degree of vestibulospinal input will be
increased when there is a loss or decrease in somatosensory information (Dietz, 2002).
In summary, gait is a complex behavior. A stable gait is characterized by postural
control, which may be accomplished through the production of coordinated rhythmic patterns of
muscle activation in the lower extremities and trunk and which moves the body forward in the
desired direction, maintaining the body’s center of mass and center of pressure within the
established base of support, producing the needed posture dynamic stability throughout
locomotion.
As a result, during a stable gait pattern, the body can respond to environmental
challenges, such as avoiding obstacles; negotiate uneven terrain; and change speed and direction
as required (Shumway-Cook & Woollacott, 2012). A disruption in the somatosensory system
may result in decreased gait modulation and adaptation, interfering with and disturbing a normal
gait cycle. A gait cycle is a series of cyclical movements, beginning when the foot contacts the
ground, which is most often the heel. This is denoted as the 0% point and is beginning of the
gait cycle, which is also known as heel contact or heel strike. The gait cycle is 100% complete
when the same foot again makes contact with the ground (Neumann, 2002). A stride, which also
is another term for gait cycle, is the events and their sequences that take place between
successive heel contacts of the same foot. A step, on the other hand, is the sequence of events
that occurs within successive heel contacts of opposite feet. Therefore, a gait cycle has two
steps: a right step and a left step (Neumann, 2002).
A gait cycle may be simply described by its most basic spatial descriptors, which include
the length of a stride and the length of a step. Stride length may be defined as the distance
between two successive heel contacts of the same foot, whereas step length may be defined as
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the distance between successive heel contacts of the two different feet. A normal stride length is
approximately 72 cm (Neumann, 2002). Step width is also an important spatial descriptor of gait
and may be defined as the lateral distance between the heel centers of two consecutive foot
contacts. Step width is normally between 7 and 9 cm (Neumann, 2002). Furthermore, foot angle
may be defined as the angle between the line of progression of the body and the long axis of the
foot. A normal foot angle is 7 degrees (Neumann, 2002).
The gait cycle may be further divided into two major phases: stance and swing
(Neumann, 2002). The stance phase begins at right heel contact and continues as long as the
right foot remains on the ground. The stance phase ends when the right toe comes off the
ground. The swing phase begins when the right toe lifts off the ground and ends when the right
heel makes contact with the ground once again. Normally, individuals will spend 60% of their
time in stance phase and 40% of their gait cycle in swing phase (Neumann, 2002).
The basic temporal gait descriptors consist of cadence, stride time, and step time
(Neumann, 2002). Cadence may be defined as the number of steps per minute; this may also be
referred to as step rate. Additionally, stride time is defined as the time for a full gait cycle, and
step time is defined as the time for completion of a right or a left step (Neumann, 2002).
Walking speed, which is a combination of spatial and temporal measures, informs the distance
covered in a given amount of time and may be the best functional measure of an individual’s
ability to walk. Normal gait speed is 1.37 m/s (Neumann, 2002).
The adaptation of gait to environmental demands depends in part upon the somatosensory
system, which consists of various sensory and proprioceptors that provide the input to modulate
the gait pattern. The proprioceptors convey information about the body and the environment to
the spinal cord via afferent nerves (Dietz, 2002). However, these are the same nerves in which
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chemotherapy agents exert their toxic affect. Tofthagen and colleagues (2012) found that as the
chemotherapy dosages increased, the presences of neuropathic symptoms increased and muscle
strength and balance decreased, causing greater difficulty in performing the tasks of walking and
driving.
Although gait is a subconscious and highly reproducible movement performed daily,
previous research suggests that when certain gait characteristics deviate from the normal, an
individual may be at higher risk for falls. Research indicates that the majority of falls
experienced by the elderly will occur during walking. As with individuals with CIPN, aging will
result in desensitization of motor units, as well as decreased perceptions of high-frequency
vibrations, touch, proprioception, and pressure stimuli, indicating a disturbed somatosensory
system (Prince, Corriveau, Hebert, & Winter, 2007). Further investigation has shown that
elderly individuals who fall will display slower gait speeds, decreases in step length, and
increases in double support times (Shumway-Cook & Woollacott, 2012). Additionally, elderly
adults who fall will exhibit increased variability within swing time and stride length, which has
been shown to predict fall risk (Verghese et al., 2009). Increased variability within
spatiotemporal gait parameters has been associated with increased fall risk (Maki, 1997)
Falling is a significant event, especially for older adults, as falls have been linked to
serious injuries and disabilities, loss of independence, and increased mortality. Twenty-three
percent of falls in adults aged 65–69 resulted in death, with the rate climbing as high as 50% of
falls resulting in death for adults aged 85 or older. It is estimated that of the 1.6 million new
cancer diagnoses in 2013, 77% were individuals over the age of 55 (Alamgir et al., 2012).
Previous studies have indicates that 20% of patients with CIPN may fall, which is a higher
percentage than age-matched controls (Mohile et al., 2009, 2011; Tofthagen et al., 2012). Stone
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and colleagues (2012) conducted a 6-month prospective study of cancer patients and found that
50.3% of the patients fell during the follow-up period. More significantly, more than one-third
of the falls resulted in soft tissue injuries and 3.2% resulted in fractures. Bylow et al. (2008)
reported that 34% of prostate cancer patients undergoing androgen deprivation therapy fell over
the course of 6 months. Bylow et al. also noted that these patients experienced significant
deficits in physical performance as measured by reduced gait speed, balance, and lower body
strength. In a very recent study, Gewandter and colleagues (2013) investigated the correlations
between chemotherapy-induced peripheral neuropathy, functional impairments, and prevalence
and falls. Of the 471 participants with CIPN, 12% reported having fallen in the 3 months prior to
the study and 27% of the participants had impairment in functional capacity. The participants
who reported a fall also had higher (worse) sensory and motor neuropathy scores. Those who
fell reported struggling to hold a pen, which resulted in difficulty writing, as well as trouble with
walking (Gewandter et al., 2013).
A study conducted by Tofthagen et al. (2012) evaluated the risk factors for falls in a
group of patients with CIPN. The participants received paclitaxel, docetaxel, oxaliplatin, or
cisplatin and reported at least one symptom of CIPN. Tofthagen and colleagues found that fallers
received higher cumulative doses of chemotherapy and a higher number of neuropathic
symptoms as noted by higher score on the Chemotherapy Induced Peripheral Neuropathy
Assessment Tool self-report questionnaire as a whole, as well as on both the symptom
experience and interference items of the questionnaire. The participants whom fell more also
reported more severe muscle weakness, loss of balance, and increased interference with walking
and driving. An interesting finding was that participants who received paclitaxel or docetaxel
were more likely to have fallen then those who received a platinum-based agent, such as
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okaliplatin. It was also interesting to note that Tofthagen and colleagues did not find a
significant difference between fallers and nonfallers in terms of age, gender, stage of disease, or
any other demographic characteristic (Tofthagen et al., 2012)
Although the literature often generally cites that cancer patients report functional
impairments, such as difficulties in walking, there is limited research examining specific gait
parameters deficits. Gait parameters are significant because research shows that spatiotemporal
gait characteristics, such as cadence, stride length, swing, double support, stride length
variability, and swing time variability, may be indicators of risk for falling. Specifically,
research indicates that slower gait speeds, decreases in step length, and increases in double
support times may increase the risk of falling (Toulotte et al., 2006; Verghese et al., 2009).
Similar to individuals with CIPN, aging will result in desensitization of motor units, as well as
decreased perceptions of high-frequency vibrations, touch, proprioception, and pressure stimuli,
indicating a disturbed somatosensory system (Prince et al., 2007).
More current research has also shown that cancer patients may display a decrease in
postural stability as a result of somatosensory changes that occur as a result of taxane
chemotherapy (Tofthagen et al., 2012; Wampler et al., 2007). Specifically, Wampler and
colleagues (2007) conducted a prospective study that evaluated postural stability of women who
received paclitaxel or docetaxel for treatment of breast cancer and compared them to matched
health controls. Because vision acuity plays a role in postural control, as well as in the
neurological and visual system, inclusion criteria required participants to have a corrected lowcontrast visual acuity better than 20/60 and corrected high-contrast visual acuity better than
20/40 (Wampler et al., 2007).
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The participants in both the breast cancer and healthy control groups completed one
testing session each. To establish intrarater reliability, women in the breast cancer group
returned and repeated all tests within 1 week of initial testing. The participants in the breast
cancer group were tested within 30 days of completing the final treatment of taxane infusion.
Testing included several quantitative peripheral neuropathy measures, which included the total
neuropathy score, the modified neuropathy score, quantitative touch thresholds, quantitative
vibration thresholds and nerve conduction studies (Wampler et al., 2007).
Several measures were used to assess postural control. Center of pressure (COP) data
were collected using a Kistler force plate to assess stability under four static positions: eyes open
with head straight, eyes open with head back 40°, eyes closed with head straight, and eyes closed
with head back 40°. The NeuroCom Sensory Organization Test (SOT) was used to assess
dynamic postural stability by way of a composite equilibrium score and a mean equilibrium
score. The SOT required the participants to stand as steady under six different conditions. Three
trials were performed for each condition. The six conditions challenged the sensory system and
increased in difficulty. The first condition required the participants to keep their eyes open on a
stable platform and a nonmoving visual surround. The tests then progressed by removing visual
feedback (by closing eyes), altering visual feedback (by moving the surround), or altering
somatosensory feedback (rotating the platform in the sagittal plane). The calculated equilibrium
score represented the amount the participant swayed during the various conditions. Also
included was the Timed Up and Go (TUG) test, which has been established as a clinical measure
of balance that assesses the relationships between the various measures of postural control
(Wampler et al., 2007).
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Wampler and colleagues (2007) found that the breast cancer patients treated with taxane
chemotherapy experienced a mild yet significant peripheral neuropathy and a significant increase
in mean TUG scores when compared to the healthy controls. Furthermore, the participants with
breast cancer displayed poorer static and dynamic postural control, especially during the
conditions that required the participants to close their eyes, which required the participants to
increasingly rely on their somatosensory and vestibular input for postural stability. Wampler and
colleagues (2007) concluded that women treated with taxanes may experience significant
changes in postural stability as a result of their treatment, which may cause the neurotoxic of
effect of taxane on the somatosensory systems and the subsequent changes that occur as a result
of the neurotoxicity. Furthermore, it was noted that while the severity of the peripheral
neuropathy experienced by the participants in this study was mild, the COP velocities, as
measured by the force plate, as well as their SOT scores from their first three conditions, were
comparable to diabetic individuals diagnosed with severe neuropathy. (Wampler et al., 2007).
An additional interesting finding from the study conducted by Wampler and colleagues
(2007) was that the modified TNS was moderately correlated with the total SOT score (r = -.66,
p = .02) and explained just 44% of the variance in SOT scores. This suggested that other
pathological changes may be occurring as the result of chemotherapy and may contribute to
postural instability (Wampler et al., 2007). Tofthagen and colleagues (2012) suggested that it is
important to note that other factors may contribute as well. Treatment-related side effects, such
as fatigue, generalized weakness, atrophy, anemia, and poor performance status, may also
increase fall risk in those who undergo chemotherapy for treatment of cancer. Generalized
weakness may be the result of anemia, fatigue, and muscle weakness. Anemia, which is a
common side effect of cancer treatment, reduces the amount of red blood cells in the body and
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thus reduces the oxygen-carrying capability. This may result in tiredness and fatigue, which may
be primary factors in fall incidences (Tofthagen et al., 2012).
Although there has been a minimal amount of research done with respect to the
mechanisms of falls often reported by cancer patients, the effects that peripheral neuropathy has
on gait have been well documented within the diabetic population. Specifically, it has been
demonstrated that individuals with diabetic peripheral neuropathy generally display a gait that is
more conservative and may be characterized by slower walking velocities and smaller step sizes
(Paul et al., 2009; Wrobel et al., 2009). Furthermore, as many as 62% of diabetics with
peripheral neuropathy may fall (Wallace et al., 2002).
Similar to chemotherapy-induced peripheral neuropathy (CIPN), diabetic peripheral
neuropathy (DPN) targets both sensory and motor fibers and is progressive in nature. Large- and
small-diameter nerve fibers are affected, resulting in attenuated sensory nerve conduction, which
includes large fiber thresholds for vibration and joint positions, as well as neurogenic atrophy
due to axonal degeneration of motor fibers (Andersen et al., 1997; Dyck & Thomas, 1999; Horak
et al., 2002)
Patients with DPN may experience symptoms that are sensory in nature and may include
burning, tingling, shooting (“electric shock”), lancing (stabbing), and numbness. Symptoms may
be present in both the upper and lower extremities and follow the “glove and stocking”
distribution pattern, in which symptoms may initially present in the toes and fingers and progress
proximally. Individuals may also experience motor deficits, characterized by weakened muscles,
particularly in the lower extremity. DPN may also be the result of disruptions in the anatomy
and function within the somatosensory system, which may be caused by endoneurial hypoxia
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brought on by poor oxygen diffusion to the small blood vessels of the lower limbs (Tesfaye &
Selvarajah, 2011).
The pathophysiological mechanisms of DNP are not completely understood but may be
related to the intermittent hyperglycemic damage of neurons that may increase the spontaneous
C-fiber firing, which may be the result of remodeling of voltage-gated ion channels
(Shankarappa et al., 2011). Additionally, several other mechanisms have been postulated, such
as changes in the disruption and expression of calcium and sodium channel, altered expression of
neuropeptides and peripheral blood flow, atrophy, and degeneration to axons, damage to small
fibers. Lastly, possible mechanisms may also include an increase in oxygen-free radicals, which
cause oxidative stress and ischemia of nerves, mitochondrial disruptions, and reduced
intraepidermal nerve fiber density and autonomic dysfunction (Kaur, Pandhi, & Dutta, 2011;
Tesfaye & Selvarajah, 2011). It has also been proposed that DPN is caused by endoneurial
hypoxia brought on by poor oxygen diffusion to the small blood vessels of the lower limbs.
Despite the uncertainty in pathophysiology, it is clear that peripheral neuropathy affects both
sensory and motor fibers and is progressive in nature. Large- and small-diameter nerve fibers are
affected, resulting in attenuated sensory nerve conduction, which includes large-fiber thresholds
for vibration and joint positions. Small-fiber thresholds for pain and temperature are also
affected (Dyck & Thomas, 1999; Horak et al., 2002).
In addition to a decrease in nerve conduction information resulting in attenuated afferent
and proprioceptive information, individuals with diabetic peripheral neuropathy also exhibit
weakened knee and ankle muscle strength caused by neurogenic atrophy due to axonal
degeneration of motor fibers (Andersen et al., 1997; Thomas & Tomlinson, 1993). There is a
significant decrease in muscle compartment cross-sectional area in both the proximal and distal
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levels of the lower leg, resulting in impaired ankle dorsiflexors and plantarflexors (Andersen et
al., 1997).
Thus, individuals with DPN often display altered gait patterns, which may be
characterized as slower, with shortened stride lengths and increased base widths, stride times,
and double support times compared to age-matched controls (Allet et a., 2008; Paul et al., 2009;
Wrobel et al., 2009). The altered gait patterns may be due to the impaired proprioceptors and
sensorimotor functions, which negatively affect the afferent feedback that is necessary to
successfully modulate locomotion (Andersen et al., 1997; Dyck & Thomas, 1999; Horak et al.,
2002; Shankarappa et al., 2011).
Individuals with diabetic peripheral neuropathy may display gait patterns characterized
by slower speeds, shortened stride lengths, greater double support times, decreased ankle
moments and powers, and decreased vertical and anterior–posterior ground reaction forces.
Dingwell and Cavanagh (2001) investigated if these changes also resulted in locomotor
variability, as increased locomotor variability is associated with increase incidences of falls.
Participants included 14 diabetic individuals with significant neuropathy, as determined by
Semmes-Weinstein filaments and a biothesiometer for vibration testing. Participants were
compared to 12 gender-, age-, height-, and weight-matched healthy controls (Dingwell &
Cavanagh, 2001).
Three strain gauge electrogoniometers were placed across the approximate joint centers
of the hip, knee, and ankle of the right leg to measure sagittal plane motion. To measure upperbody dynamic stability, a triaxial accelerometer was attached to the base of the sternum to
measure accelerations of the upper body in the anterior–posterior, vertical, and mediolateral
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directions. Each participant walked around a 200-m open-level indoor walking track at a natural
pace. Data were collected at 66.7 Hz (Dingwell & Cavanagh, 2001).
Dingwell and Cavanagh (2001) found that the participants with peripheral neuropathy
walked slower and took smaller steps compared to the control group. Furthermore, the
participants with peripheral neuropathy displayed significant increases in locomotor variability,
and variability in the gait cycle was most highly correlated with falls. Specifically, as variability
increased, fall risk increased (Dingwell & Cavanagh, 2001).
The findings by Dingwell and Cavanagh (2001) have since been confirmed in various
other studies. Paul and colleagues (2009) evaluated gait parameters of individuals with diabetic
peripheral neuropathy (DPN) with individuals without DPN. Of the 30 participants recruited, 15
had DPN whereas the remaining 15 did not have DPN. Paul et al. used the GAITRite walkway
to evaluate various spatiotemporal parameters, such as step length and duration, duration of
single and double support, velocity, and cadence. The primary outcome was gait velocity. For
all of the gait variables measured, Paul and colleagues found that there was a statistically
significant difference in gait parameters within individuals with DPN. Specifically, individuals
with DPN had significantly slower walking velocities, as well as shorter step length, but longer
step times. Individuals with DPN also displayed greater double support times and a slower
cadence compared to individuals without DPN (Paul et al., 2009).
Furthermore, Camargo et al. (2015) investigated the relationships between balance, ankle
muscle strength, and spatiotemporal gait parameters in individuals with diabetic peripheral
neuropathy. The spatiotemporal gait parameters were evaluated by recording the time it took the
participants to walk predetermined distances during self-selected walking speeds and maximal
walking speeds. Balance was evaluated using the Timed Up and Go (TUG) test. Compared to
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healthy controls, individuals with DPN displayed significantly different spatiotemporal gait
parameters and scores on the TUG test. Specifically, individuals with DPN had shorter step
lengths and slower cadence and gait speeds in both self-selected walking speed and maximal
walking speed. Results also indicated the individuals with DPN took greater amounts of time to
perform the test, suggesting DPN individuals display functional deficits when ambulating
(Camargo et al., 2015).
Wuehr and colleagues (2014) evaluated the influence of peripheral neuropathy on
walking patterns of 18 neuropathic individuals compared to age-matched controls. The
participants presented with significant peripheral neuropathy in their legs and feet as a result of
various etiologies that consisted of type 2 diabetes, vitamin B12 deficiency, ethyl toxicity, and
idiopathic peripheral neuropathy. Walking velocity, as well as cadence, base width, stride
length, stride time, double support time, double support time percentage, swing time percentage,
and stance time percentage, were analyzed for each trial and leg separately using the GAITRite
system.
Wuehr and colleagues (2014) found that peripheral neuropathy directly affected gait
variability between strides in both the mediolateral plane (base width) and fore–aft plane (stride
time and stride length). Specifically, individuals with peripheral neuropathy displayed
significant variability in heel strike magnitudes, regardless of walking speed, which is significant
considering mediolateral adjustments are primarily controlled by integrated sensory feedback
(Wuehr et al., 2014). Fore–aft locomotion, which is thought to be stabilized by biomechanical
regulation, should not be affected by a deficit in the sensory system. However, individuals with
peripheral neuropathy, and thus deficient peripheral sensory systems, displayed significant
variability in both stride length and stride time. Variability was more present at slower walking
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speeds, which is when locomotion is relies highly on active sensory feedback (Wuehr et al.,
2014).
In summary, many patients who receive chemotherapy as part of their treatment for
cancer are likely to experience CIPN in one form or another, which can cause a variety of
debilitating symptoms due to peripheral nerve toxicities caused by the chemotherapy agents
(Murillo et al., 2008; Visovsky et al., 2007; Wilkes, 2007). Specifically, chemotherapy agents
may disrupt axonal transport, resulting in diminished or absent deep tendon reflexes,
hyperesthesias, hypoesthesias, paresthesias, pain, loss of temperature and vibration sense, loss of
proprioception, and motor neuropathy (Murillo et al., 2008; Visovsky et al., 2007; Wilkes, 2007).
Cancer survivors who receive chemotherapy for cancer treatment may experience a disruption to
the somatosensory systems which may negative effect the sensory feedback that is necessary to
produce a coordinated and balanced gait (Magill & Anderson, 2013; Murillo et al., 2008;
Visovsky et al., 2007; Wilkes, 2007). Research indicates that cancer survivors who have
undergone chemotherapy report gait disturbances and higher incidences of falls (Bylow et al.,
2008; Gewandter et al., 2013; Mohile et al., 2009, 2011; Stone et al., 2012; Tofthagen et al.,
2012; Wampler et al., 2007). Although the literature has not evaluated specific changes in
spatiotemporal gait parameters in cancer patients, previous research indicates that individuals
afflicted with peripheral neuropathy as a result of various etiologies will display altered gait
patterns characterized by smaller step and stride lengths, wider step widths, increased double
support times, and slower walking speeds (Dingwell & Cavanagh, 2001; Toulotte et al., 2006;
Verghese et al., 2009; Wuehr et al., 2014). Furthermore, individuals with peripheral neuropathy
will display increased variability within these same parameters, which is significant considering
that increased variability is associated with increased falls (Dingwell & Cavanagh, 2001; Maki,
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1997). As a result, patients experiencing peripheral neuropathy, regardless of the etiology,
experience fall rates that are higher than individuals without peripheral neuropathy. However,
investigation of changes within spatiotemporal gait parameters has provided insight as to the
changes in gait that individuals with peripheral neuropathy due to diabetes and vitamin
deficiencies. Research has not investigated changes within the spatiotemporal gait parameters of
cancer patients experiencing CIPN. Therefore, considering the common pathophysiologies of
peripheral neuropathy between diabetic peripheral neuropathy and chemotherapy-induced
peripheral neuropathy and evaluating spatiotemporal gait patterns such as stride length, cadence,
and velocity within individuals diagnosed with CIPN may provide insight into the gait
interference and incidences of falling that patients with CIPN have reported within the literature.
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Chapter III

METHODS
Cancer survivors who receive chemotherapy for cancer treatment may experience a
disruption to the somatosensory systems, which may negatively affect the sensory feedback
which aides in the coordinated and balance required in gait (Magill & Anderson, 2013; Murillo
et al., 2008; Visovsky et al., 2007; Wilkes, 2007). Research indicates that cancer survivors who
have undergone chemotherapy report gait disturbances and higher incidences of falls (Bylow et
al., 2008; Gewandter et al., 2013; Mohile et al., 2009, 2011; Stone et al., 2012; Tofthagen et al.,
2012; Wampler et al., 2007). Although the literature has not evaluated specific changes in
spatiotemporal gait parameters, research has indicated an association between cadence, stride
length, swing, double support, stride length variability, and swing time variability. Specifically,
research indicates that slower gait speeds, decreases in step length, and increases in double
support times may increase the risk of falling (Toulotte et al., 2006; Verghese et al., 2009).
Thus, evaluating spatiotemporal gait patterns within individuals diagnosed with CIPN who are at
a risk for falls may provide insight into the gait interference that increases the risk of falling as
reported in the literature by patients with CIPN.
Therefore, the purpose of this study is to assess whether chemotherapy-induced
peripheral neuropathy is associated with spatiotemporal gait adaptations in posttreatment adult
cancer survivors when compared to healthy, disease-free, age- and morphologically matched
controls.
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Participants
Sixteen participants between the ages of 50 and 70 were recruited for participation. Eight
of the participants had a histologically confirmed stage 2–3 breast or colorectal cancer diagnosis
with a confirmed treatment plan consisting of taxane- or oxaliplatin-based chemotherapy as
confirmed by an oncologist. Participants also had a confirmed diagnosis of chemotherapyinduced peripheral neuropathy according to the Common Terminology Criteria for Adverse
Events (CTCAE) version 4.0.
Subjects were excluded if they had a history of peripheral neuropathy (i.e., hereditary
peripheral neuropathy associated with nutritional agents and paraneoplastic), known peripheral
neuropathy, or diseases that may contribute to peripheral nerve damage, such as diabetes, renal
insufficiency, alcohol abuse, vitamin B12 deficiency, HIV, and vasculitis. Subjects were
excluded if they had central or peripheral neurologic disease, brain or spinal cord metastases,
orthopedic problems that affect balance, or vestibular system or visual disease. Subjects were
excluded if they had corrected low-contrast visual acuity worse than 20/60 and a corrected highcontrast visual acuity worse than 20/40. Subjects, who had participated in regular exercise, as
defined as 150 min of light-to-moderate intensity exercise per week over the past year, were
excluded from this trial. Subjects were also excluded if they used a walking aide.
Design
This study was a quasi-experimental design.
Variables
The variables included both spatial and temporal gait parameters. The spatial gait
parameters consisted of step length and base of support. Step length was measured from the heel
center of the current footprint to the heel center of the previous footprint on the opposite foot, by
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the GAITRite walking system. H-H base of support, or base width, was measured as the vertical
distance from the heel center of one footprint to the line of progression formed by two footprints
of the opposite foot, as measured by the GAITRite walking system.
The temporal gait parameters consisted of velocity, step time, swing time, single support
time, and double support time. Velocity was defined as dividing the distance traveled by the
ambulation time and was expressed in centimeters per second (cm/sec). Step time was defined
as the time in seconds elapsed from first contact of one foot to first contact of the opposite foot.
Swing time was initiated with the toe off and ended with the heel strike. It was defined as the
time elapsed between the last contact of the current footfall to the first contact of the next footfall
on the same foot and was expressed in seconds (s). Single support was defined as the time
elapsed between the last contact of the current footfall to the first contact of the next footfall of
the same foot and was measured in seconds (s). Swing time is equal to the single support time of
the opposite foot. Lastly, double support time was defined as the period when both feet are on
the floor. Initial double support occurs from the heel contact of one footfall to the toe-off of the
opposite footfall and is measured in seconds (s). Fall risk was defined as the time it took to
complete the Timed Up and Go test. Research suggested that a time of greater than 10.7 s
indicated risk for falls (Jernigan et al., 2012).
Measurements
The GAITRite system was used to measure all spatio temporal parameters of gait. It is an
electronic pathway that is 8.2 m in length. Through an interface bale, the electronic pathway
connects to a personal computer. The electronic pathway is made up of a series of sensory pads
that are inserted in grid formation between a layer of vinyl (top cover) and foam rubber (bottom
cover). The active area is 61 cm wide and 732 cm long. The sensors are placed 1.27 cm apart
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and are activated by mechanical sensors. There are a total of 27,648 sensors. Data from the
activated sensors are collected by a series of onboard processors and transferred to the computer
through a serial port. The sampling rate of the system is 8 Hz. Visually, the walkway resembles
a carpet runner and is portable (Webster, Wittwer, & Feller, 2004).
Fall risk was assessed using the valid and reliable Timed Up and Go test (TUG), which is
a mobility test used to measure basic mobility skills (Webster, Wittwer, & Feller, 2004). The
measurement outcome for the TUG is the time it takes to rise up out of a chair, walk 3 m away
from the chair, walk 3 m back to the chair, and return to the seated position. The time it takes to
complete this task is recorded. Previous research indicates that a time of greater than 10.7 s
indicates risk for falls (Jernigan et al., 2012).
Procedures
Potential subjects were recruited through the placement of an Institutional Review Board
(IRB)–approved advertisement flyer (see Appendixes A and B) on bulletin boards located
throughout the Seton Hall University (SHU) community, as well as the surrounding SHU
community. Participants were also recruited from Saint Michael’s Medical Center, located in
Newark, NJ. See Appendix E for the research flyer. A snowballing sampling technique method
was used to recruit participants (Portney & Watkins, 2009).
Upon seeing the study research flyer, potential subjects contacted the primary
investigator (PI) by either the e-mail address or phone number listed on the flyer (see Appendix
B). Upon being contacted, the PI scheduled a meeting with the potential subject at the South
Orange Campus of Seton Hall University, 400 South Orange Avenue, South Orange, New
Jersey, in Corrigan Hall Room 67 (Functional Human Performance Lab) in order to review the
inclusion and exclusion criterion for participation. The PI also met participants at the Cancer
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Center at Saint Michael’s Medical Center, which was a second testing site. The subjects were
instructed to wear a T-shirt or sweatshirt, shorts or sweatpants, and a pair of comfortable walking
shoes or sneakers to the testing sessions. Upon arrival to the testing session site, subjects were
required to read an informed consent form. Subjects were given the opportunity to ask
questions. If, after reviewing the consent forms and asking any related questions, the potential
subjects were still willing to volunteer to participate, they were required to sign the consent
forms and were advised that they could withdraw from the study at any time.
Following the signing of the informed consent forms, the PI administered the prescreen
tool (see Appendix C) to those who met the study inclusion and exclusion criteria. The subjects’
responses were recorded. An answer of yes to any of the questions indicated that the subject did
not fit the inclusion and exclusion criteria and thus could not participate in the present study. If
the subject did not qualify for participation, the subject was thanked for being willing to
volunteer. Those subjects who met the study inclusion criteria proceeded to the data collection
portion of the study.
Data collection began with the completion of the top portion of the Participant Data
Collection Sheet (see Appendix D), which included the subject’s cancer diagnosis, name of the
chemotherapy agent received, age, sex, height, and weight. Prior to the collection of the
spatiotemporal parameters of gait using the GAITRite system and risk of falls by the Timed Up
and Go test, subject height and right/left leg length were measured (from the greater trochanter to
the floor) using a standardized, flexible cloth tape. These data were required by the GAITRite
software.
Next, following standard protocol, the Timed Up and Go test was performed to assess fall
risk. The Timed Up and Go test required the subjects to raise their body out of a chair, walk 3 m
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down a hallway, turn around, walk 3 m back to the chair, and sit back down in the chair. To set
up the test, a 3-m (9.8-ft.) walkway was measured and marked on the floor using colored tape.
The floor of the walkway was clear of any objects. A standard-height chair (seat height, 46 cm;
arm height, 67 cm) was positioned at the beginning of the walkway. The subjects began by
sitting on the standard chair, placing their back against the chair, and resting their arms by their
sides.
The PI demonstrated the test prior to the subject performing the test. After the
demonstration, PI instructed the subject to walk at a self-selected pace. When the subject was
ready, the PI said “Go,” indicating to the subject to get up out of the chair, walk the 3-m distance
away from the chair, walk the 3-m distance back to the chair and sit back down. The stopwatch
was started upon the “Go” command from the PI and was stopped when the subject’s butt made
contact with the seat upon sitting back down. The time it took to complete the test was recorded
on the Individual Participant Data Collection Sheet (see Appendix B). Fall risk was indicated by
a timed score of greater than 10.7 (Jernigan et al., 2012)
Jernigan and colleagues (2012) suggested that because in the clinical setting, sensitivity is
the most important measure, as high sensitivity corresponds to more true positives and fewer
false negatives. The Timed Up and Go test is a good test to assess fall risk due to its high
sensitivity of 90%, 88.5% specificity, and high diagnostic accuracy at 88.9% when a modified
cutoff score is applied. Subjects who volunteered to be in the control group were also assessed
for fall risk.
After the completion of the Timed Up and Go test, the GAITRite was used to compute
the spatiotemporal gait parameters (step length, step time, and walking speed). Before initiating
walking on the GAITRite, the PI set up the location. For each trial, subjects were instructed to
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initiate walking from a non sliding standing spot mat located at the midpoint of the start line
placed 2 m before the beginning edge of the GAITRite carpet. This allowed walking to be
initiated from the same location at every trial and permitted a steady state of ambulation to be
achieved prior to stepping on the GAITRite walkway. The subjects were informed to negotiate
the entire length of the 5.18-m GAITRite carpet walkway at a steady pace while looking straight
ahead. Three trials were performed.
Data Analysis
The present study contained two groups: a control group, which consisted of healthy,
disease free, age and morphologically matched controls, and an intervention group, which
consisted of cancer survivors diagnosed with CIPN. The independent variable was the presence
of CIPN. There were multiple dependent variables, which included the participants’ TUG score
and spatiotemporal gait parameters obtained from the GAITRite. Thus, the research question
was answered by using a one-way MANOVA comparing each of the spatial and temporal
variables between the two groups. An alpha level of 0.05 was used (Field, 2009).
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Chapter IV
RESULTS

The purpose of this study was to investigate if changes exist in the spatiotemporal gait
parameters of cancer patients who have completed chemotherapy for the treatment of cancer
compared to age and morphological matched controls. A total of 16 subjects participated in the
present study. Of the 16 subjects, 8 had CIPN, and the remaining 8 subjects were the age and
morphologically matched controls.
Table 1 indicates that both of the groups had 6 females and 2 males. Table 2 indicates
that the mean age of the CIPN participants was 61.38 years (SD = 7.24) and the mean age of the
control participants was 62.25 years (SD = 3.77). Table 2 shows that the mean weight of the
CIPN participants was 76.45 kg (SD = 18.48), whereas the mean weight of the control
participants was 72.42 kg (SD = 8.88). Table 3 indicates that 5 of the participants had breast
cancer and 3 participants had colon cancer. Of the types of chemotherapy received, 1 participant
received pacelitaxel, 4 participants received taxanes, and 3 participants received oxaliplatin.
Table 4 indicates that age was normally distributed for CIPN D (7) = .224, p > .05 and
control, D (7) = .122, p > .05. Table 4 shows that weight was normally distributed for CIPN D
(7) = .584, p> .05 and control, D (7) = .117, p> .05. Table 4 also denotes that height was
normally distributed for CIPN D (7) = .832, p> .05 and control D (7) = .936, p> .05. Lastly, as
indicated in table 5, BMI was normally distributed for CIPN D (5) = .901, p> .05 and control, D
(7) = .884, p> .05.
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Table 1
Participant Gender
Females

CIPN
Control
CIPN
Control

Males

Participant type

N
6
6
2
2

Table 2
Descriptive Statistics

Age (yrs.)
Weight (kg)
Height (cm)
BMI (kg/m2)

Participant type
CIPN
Control
CIPN
Control
CIPN
Control
CIPN
Control

N
8
8
8
8
8
8
8
8

Mean
61.38
62.25
76.45
72.42
158.05
167.90
27.71
24.85

Std. deviation
7.42
3.77
18.48
8.88
14.35
9.44
6.34
2.37

Table 3
Cancer Participant Descriptive
Chemotherapy type
Cancer type

n

Breast Cancer

5

Colon Cancer

3

Paclitaxel
1

Taxane

Oxaliplatin

4
3

Std. error
mean
2.63
1.33
6.53
3.14
5.07
3.34
2.24
.84
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Table 4
Evaluating Descriptive Data for Normal Distribution
Participant
type
Age
CIPN
Control
Weight (Kg) CIPN
Control
Height (cm) CIPN
Control
BMI
CIPN
Control

Kolmogorov-Smirnov
Statistic
df
Sig.
.159
8
.200
.267
8
.097
.189
8
.200
.223
8
.200
.289
8
.048
.157
8
.200
.210
8
.200
.265
8
.103

Shapiro-Wilk
Statistic
df
.888
8
.861
8
.937
8
.859
8
.832
8
.936
8
.901
8
.884
8

Sig.
.224
.122
.584
.117
.062
.576
.296
.205

Table 5 indicates that there was equal variability with age, F (1, 14) = 4.01, p > .05.
Table 5 shows that the assumption of homogeneity of variance for weight had been violated, F
(1, 14) = 6.59, p < .05. Table 5 shows that there was equal variability with height, F (1, 14) =
.145, p > .05, but homogeneity of variance was not violated. Lastly, as displayed in Table 5, the
assumption of homogeneity of variance for BMI had also been violated, F (1, 14) = 10.10, p <
.05.
Table 5
Evaluating the Descriptive Data for Homogeneity of Variance
Age (years)
Weight (kg)
Height (cm)
BMI

Levene statistic
4.01
6.59
.145
10.10

df1
1
1
1
1

df2
14
14
14
14

Sig.
.065
.022
.709
.005

An independent t test was used to evaluate if the participant characteristics of the CIPN
group were significantly different or similar to the participant demographics of the control group.
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As four independent t tests were run on the same data, a Bonferroni correction was applied to
reduce the risk of making type 1 error (Field, 2009). As indicated in Table 6, there was no
significant difference in age, t (14, = –.297, p > .05 or weight, t (10.071) = .556, p > .05, between
the two groups. Table 6 also denotes that there was no significant difference in height, t (14) = 1/622, p > .05, or BMI, t (8.913) = 1.196, p > .05, between the two groups. Therefore, there was
no significant differences between the participant characteristics of the two groups other than the
presence of chemotherapy-induced peripheral neuropathy.
Table 6
Independent t Test to Compare Descriptive Data Means

Age
Weight
(kg)
Height
(cm)
BMI

Equal variances assumed
Equal variances not assumed
Equal variances assumed
Equal variances not assumed
Equal variances assumed
Equal variances not assumed
Equal variances assumed
Equal variances not assumed

t test for equality of means
t
df
Sig. (2-tailed)
-.297
14
.771
-.297
10.385
.772
.556
14
.587
.556
10.071
.590
-1.622
14
.127
-1.622
12.100
.131
1.196
14
.251
1.196
8.913
.262

With the results of the independent t test indicating that two groups were the same with
regard to their demographic characteristics, a one-way MANOVA was conducted to determine if
significant differences exist between the dependent variables. Before a one-way MANOVA was
ran, the assumptions for the test were first tested. The assumptions tested consisted of
multivariate normality, the linear relationship between the dependent variables, the homogeneity
of variance–covariance matrices, and multicollinearity (Field, 2009)
The first assumption tested was multivariate normality by use of the Shapiro-Wilk test
(Field, 2009).
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Table 7
Assessing Normal Distribution of Gait Parameters
Kolmogorov-Smirnov
Shapiro-Wilk
Participant type Statistic df
Sig. Statistic df
Sig.
TUG
CIPN
.340
8
.007
.643
8
.001
*
Control
.183
8 .200
.899
8
.284
*
Velocity
CIPN
.184
8 .200
.950
8
.708
*
Control
.203
8 .200
.911
8
.358
*
R_Step_Time
CIPN
.218
8 .200
.784
8
.019
*
Control
.179
8 .200
.903
8
.308
R_Step_Length
CIPN
.291
8
.045
.791
8
.023
*
Control
.202
8 .200
.912
8
.372
*
R_HH_Base_Support
CIPN
.141
8 .200
.945
8
.658
*
Control
.219
8 .200
.943
8
.642
*
R_Swing_Time
CIPN
.172
8 .200
.937
8
.582
Control
.272
8
.083
.820
8
.046
*
R_Single_Support_Time CIPN
.228
8 .200
.881
8
.194
*
Control
.185
8 .200
.955
8
.761
*
R_Double_Support_Time CIPN
.213
8 .200
.947
8
.679
*
Control
.197
8 .200
.896
8
.265
Table 7 indicates that the data for the TUG test for the CIPN group, D (7) = .643, p < .05,
were not normally distributed. But the TUG data for the control group were normally
distributed, D (7) = .899, p > .05. Velocity data for the CIPN group, D (7) = .950, p > .05, as
well as data for the control group, D (7) = .911, p > .05, were normally distributed. Table 7
depicts that data for the right step time of the CIPN group, D (7) = .784, p < .05, were not
normally distributed, whereas data for the control group was normally distributed, D (7) = .903,
p > .05. Furthermore, CIPN data for base step length, D (7) = .791, p < .05, were not normally
distributed, whereas data for control were normally distributed, D (7) = .912, p > .05. Base of
support data for both the CIPN group, D (7) = .945, p > .05, and control group, D (7) = .943, p >
.05, were normally distributed. Swing time data for the CIPN group, D (7) = .937, p > .05, were
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normally distributed, whereas swing time data for the control group were not normally
distributed, D (7) = .820, p < .05. Table 7 indicates that single support time for the CIPN group,
D (7) = .881, p > .05, and the control group, D (7) = .955, p > .05, were normally distributed.
Lastly, Table 7 depicts that double support time data for the CIPN group, D (7) = .947, p > .05,
and control group, D (7) = .896, p > .05, were both normally distributed. Although Table 7
indicates violations of the assumption of normal distribution, however, a one-way MANOVA
was still conducted, as the test is robust enough (Field, 2009).
The second assumptions tested was if there was homogeneity of variance-covariance
matrices by use of the Leven’s test (Field, 2009). Table 8 displays the results of Levene’s test,
which assesses homogeneity of variance/covariance. As indicated in Table 8, there was no
significant difference in variability for TUG data, F (1, 14) = 3.84, p > .05. Table 8 also
indicates that velocity, F (1, 14) = 32.44, p > .05, and step time, F (1, 14) = 3.28, p > .05, also
satisfied the assumption of homogeneity of variance/covariance.
Table 8
Leven Test for Homogeneity of Variance-Covariance

TUG
Velocity
R_Step_Time
R_Step_Length
R_HH_Base_Support
R_Swing_Time
R_Single_Support_Time
R_Double_Support_Time

Levene
statistic
3.84
2.55
3.28
4.00
2.58
2.56
.74
1.07

df1
1
1
1
1
1
1
1
1

df2
14
14
14
14
14
14
14
14

Sig.
.070
.133
.092
.065
.131
.132
.403
.319
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Base of support, F (1, 14) = 2.58, p > .05, and swing time, F (1, 14) = 3.84, p > .05, also
satisfied the assumption of homogeneity of variance/covariance. Lastly, as depicted in Table 8,
single support time F (1, 14) = .74, p > .05 and double support time, F (1, 14) = 1.07, p > .05,
data also satisfied the assumption of homogeneity of variance/covariance (Field, 2009).
The third assumption addressing a linear relationship between the dependent variables for
each of the independent variables using scatterplot matrices (Field, 2009). Figure 1 indicates that
there was a linear relationship between TUG and velocity for the independent variables, thus
satisfying the MANOVA assumption. Figure 2 indicates that there was a linear relationship
between step time and step length for the independent variables, thus satisfying the MANOVA
assumption.

Figure 1. Linear relationship for TUG and velocity.

Figure 2. Linear relationship for step time and step length.
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Figure 3. Linear relationship for base of support and swing time.

Figure 4. Linear relationship for single and double support time.

Figure 3 indicates that there was a linear relationship between base of support and swing

time for the independent variables, thus satisfying the MANOVA assumption. Figure 4 indicates
that there was a linear relationship between single and double support time for the independent
variables, thus satisfying the MANOVA assumption.
The last assumption test was multicollinearity by use of the Pearson’s correlation
coefficient. The dependent variables did not display a high level of correlation, which was
indicated by a Pearson product value of .90 or higher (Field, 2009). As indicated in Table 9,
none of the dependent variables were highly correlated because all Pearson correlations were
below 0.90. Thus, the assumption was satisfied (Field, 2009).
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Table 9
Pearson Correlations for Multicollinearity

Table 10 indicates the mean Timed Up and Go (TUG) time for the CPN participants was
12.33 s (SD = 6.25), whereas the mean TUG time for the control was 6.62 s (SD = 1.10). The
CIPN group had a mean step time of .55 s per step (SD = .08), whereas the control had a mean
step time of .52 s per step (SD = .02). As displayed in Table 10, the mean step length for the
CIPN group was 53.92 cm per step (SD = 23.55), whereas the mean step length for the control
was 77.15 cm per step (SD = 5.28). The CIPN group mean base of support was 8.77 cm (SD =
3.00), whereas the control group had a mean base of support of 7.87 cm (SD = 1.97). The mean
swing time for the CIPN group was .44 s per step (SD = .04), whereas the mean swing time for
the control group was .43 s per step (SD = .02). The mean single support time for the CIPN
group was .44 s per step (SD = .05), whereas the mean single support time for the control group
was .43 s per step (SD = .03). Lastly, Table 10 indicates that the mean double support time for
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the CIPN group was .24 s per step (SD = .07), whereas the mean double support time for the
control group was .18 s per step (SD = .07).
Table 10
Dependent Variable Descriptive Statistics
TUG(s)
Velocity
R Step Time
R Step Length
R HH Base Support
R Swing Time
R Single Support Time
R Double Support Time

Participant type
CIPN
Control
Total
CIPN
Control
Total
CIPN
Control
Total
CIPN
Control
Total
CIPN
Control
Total
CIPN
Control
Total
CIPN
Control
Total
CIPN
Control
Total

Mean
12.33
6.62
9.48
110.75
147.79
129.27
.55
.52
.54
53.92
77.15
65.53
8.77
7.87
8.32
.44
.43
.43
.44
.43
.44
.24
.18
.21

Std. deviation
6.25
1.10
5.24
26.79
11.69
27.65
.08
.02
.06
23.55
5.28
20.39
3.00
1.97
2.49
.04
.02
.03
.05
.03
.04
.07
.04
.07

N
8
8
16
8
8
16
8
8
16
8
8
16
8
8
16
8
8
16
8
8
16
8
8
16

Next, a one-way MANOVA was performed to determine if a significant difference
existed between the mean TUG and one or more of the spatiotemporal gait values. A one-way
MANOVA was performed due to having more than one dependent variable. Table 10 displays
the results of the one-way MANOVA.

EFFECTS OF CIPN ON GAIT AND FALL RISK

81

Table 11 indicates that there was no significant difference in TUG scores or
spatiotemporal gait parameters between the control group and participants with chemotherapyinduced peripheral neuropathy, F (8, 7) = 2.45, p > .05, partial η2 = .74. Pillai’s trace test
statistics were used because, as indicated in Table 7, there were violations of the assumptions of
normal distribution. Therefore, due to the conservative nature of Pillai’s trace, it was the more
appropriate test to use when violations existed because it is robust to these violations (Field,
2009).
Table 11
MANOVA Output

Intercept

Effect

Participant type

Pillai's Trace
Wilks'
Lambda
Hotelling's
Trace
Roy's
Largest Root
Pillai's Trace
Wilks'
Lambda
Hotelling's
Trace
Roy's
Largest Root

Value
1.00

Partial
Hypothesis Error
Eta
F
df
df
Sig. Squared
2141.86
8.00 7.00 .00
1.00
2141.86

8.00

7.00

.00

1.00

2447.83

2141.86

8.00

7.00

.00

1.00

2447.83

2141.86

8.00

7.00

.00

1.00

.26

2.45

8.00

7.00

.13

.74

.00

.74

2.45

8.00

7.00

.13

.74

2.80

2.45

8.00

7.00

.13

.74

2.80

2.45

8.00

7.00

.13

.74

Table 12 displays the results of multiple analyses of variance run to determine if any of
the dependent variables differed for the deponent variables. Because 8 ANOVAs were run, a
Bonferroni correction was applied, adjusting the alpha to decrease to risk of making a type 2
error. The original alpha level of .05 was divided by 8 to determine the new alpha level of .006.
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Using the correct alpha level, only velocity was noted to be significantly different between the
control group and CIPN group, F (1, 16) = 12.85, p = .003, partial η2 = .48.
Table 12 displays the results of multiple Kruskal-Wallis H test, which was performed
given that the data was not normally distributed. Since 8 Kruskal-Wallis H test were performed,
a Bonferroni correction was applied, adjusting the alpha to decrease the risk of making a type 2
error. The original alpha level of .05 was divided by 8 to determine the new alpha level of .006.
Effect size was calculated using the equation,

=

, where H was the value obtained in the

Kruskal-Wallis test, n² is eta squared, ‘k’ was the number of groups, and ‘n’ was the total
number of observations (Tomczak & Tomczak, 2014).
Table 12
Kruskal-Wallis H Test Output
R_HH_
R_Step_ R_Step_ Base_ R_Swing_ R_Single_
R_Double_
TUG Velocity Time Length Support
Time
Support_Time Support_Time

Chi11.29
Square
df
1
Asymp.
.001
Sig.

7.46

.40

8.04

.54

.04

.00

3.19

.006

.529

.005

.462

.833

.958

.074

1

1

1

1

1

1

1

Using the correct alpha level, velocity was found to be significantly different between the
control group and CIPN group, X²(1) = 7.46 p = .006; n² = 0.43. Step length was also found to
be significantly different between the control group and CIPN group, X²(1) = 8.04, p = .005, n² =
0.47. Lastly, the TUG time was also found to be significantly different between the control
group and the CIPN group, X²(1) = 11.29, p = .001; n² = 0.69.
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Figure 5. G-power analysis.
As indicated in figure 5, a large partial eta squared lead to a large effect size (2.85).
Additionally, it was found that the power for the present study was .87, which satisfied the .8
threshold (Field, 2009).

83

EFFECTS OF CIPN ON GAIT AND FALL RISK

84

Chapter V

DISCUSSION
With screening measures and treatment options improving, the number of people
surviving a cancer diagnosis is increasing (Siegel et al., 2012). However, many cancer survivors
are dealing with long-term physical and emotional side effects that negatively impact their health
and overall quality of life (Rowland & Bellizzi, 2014). A common functional impairment
experienced by cancer patients who received chemotherapy is chemotherapy-induced peripheral
neuropathy (CIPN) (Stubblefield et al., 2009). It is estimated that the incidence rate of CIPN is
30%–70% dependant up on various factors, such as the class of chemotherapy agent and/or the
cumulative dosage of the agent (Mantyh, 2006). Taxanes, such as paclitaxel, are commonly used
to treat breast cancer, causing CIPN in 57%–83% of patients (Stubblefield et al., 2009).
Chemotherapy-induced peripheral neuropathy symptoms are often described as
paraesthesia-like numbness and/or pain, which occurs in a stocking-and-glove distribution
(Argyriou et al., 2012). Cancer patients with CIPN often report difficulties in walking, in that
they feel unsteady and have a reduced sense of balance (Grisold, Cavaletti, & Windebank, 2012;
Visovsky & Daly, 2004; Wampler et al., 2007). The impaired balance and gait reported by
cancer patients has been linked to increased fall risk, potentially causing significant limitations in
the ability to perform tasks of daily living (Quasthoff & Hartung, 2002; Stubblefield et al., 2009;
Tofthagen et al., 2012; Windebank & Grisold, 2008). However, little is known about the specific
gait impairments that may be caused by CIPN and if these gait impairments contribute to the
increase in fall risk (Wampler et al., 2007). Furthermore, little is known about the compensation
strategies employed by cancer patients with CIPN to manage these functional deficits.
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Therefore, the purpose of this study was to investigate possible changes in spatiotemporal gait
patterns of cancer patients with CIPN.
In the present study, it was found that CIPN subjects gait velocity (110.75 cm/s) was
significantly slower than control subject’s walking velocity (147.79 cm/s). Furthermore, the step
length of those with CIPN (53.92 cm) was significantly shorter than the step length of the control
subjects (77.15 cm). This studies finding that individuals with CIPN do have slower gait
velocities is noteworthy because it supports a study done by Verghese et al. (2009) who found
that individuals with gait speeds between 70 and 100 cm/s were more like to fall then individuals
with gait speeds above 100 cm/s. Furthermore, Verghese et al. (2009) found that a decrease in
gait velocity by 10 cm/s increased fall risk by 7% and thus concluded that gait velocity is a
simple and quick way to assess fall risk.
Moreover, the CIPN participants in this current study had a gait velocity of 110. 75 cm/s
(SD = 26.79), which is above the upper threshold 100 cm/s that Verghese et al. (2009) found to
predict falls. However, the participants in the present study had a mean age of 61. 38 years (SD
= 7.42), whereas the mean age of the participants in the study by Verghese et al. (2009) was 80.5
years. Thus, despite the age difference of approximately 20 years, the difference in gait velocity
between those with CIPN and the participants in the study by Verghese et al. (2009) was 10 cm/s.
This suggests that the presence of CIPN may negatively impact individuals’ gait to the extent that
they will develop a gait pattern similar to that of someone who is 20 years their senior.
Additionally, a decrease in gait velocity was found in this study and is concerning as
decreased velocity has been found to be directly associated with an increase in fall risks, (Espy et
al., 2010). The mean Timed-Up & Go (TUG) time for those with CIPN was 12.33 seconds (SD
= 6.25), which was significantly greater than the mean TUG time for the control group which
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was 6.62 (SD = 1.10). Moreover, the mean TUG time by those with CIPN was well above the
score of 10.7 seconds which researchers suggest is indicative of fall risk (Jernigan et al., 2012).
Therefore, the results further support that those with CIPN are at a higher risk of falling.
Not only was there a significant difference in gait velocity in this study, but individuals
with CIPN consistently displayed significantly shorter step lengths; with a mean step length of
53.92 cm, which was significantly shorter than the control step length of 77.15 cm.
In the literature various clinical assessments are used to evaluate fall risk including the
Timed-Up-and-Go (TUG). While the TUG test has demonstrated its clinical effectiveness in
assessing fall risk, the TUG does not evaluate kinetic differences that are specific to the
impairment that may be influence fall risk in all populations (Schulz et al., 2010). Thus
researchers have used the Maximum Step Length (MSL) test which assesses both dynamic
balance and leg strength. Clinically, a decrease in the MSL test is associated with an increase
decade of life and performance on clinical assessments that are used to predict falls; as MSL
decrease, fall risk increases (Cho et al., 2004; Lindermann et al., 2003; Schulz et al., 2013).
Research indicates that the majority of falls experienced by the elderly and individuals with
diabetic peripheral neuropathy will have gait patterns that are consistent with shortened step
lengths (Paul, Ellis, Leese, McFadyen, McMurray, 2009; Shumway-Cook & Woollacott, 2012).
Thus, the findings in the present study of decreased step length in individuals with CIPN can be
associated with increased fall risk.
While previous research suggest that peripheral nerve dysfunction results in lower
extremity impairments and functional limitations, such as a decrease in gait speed, the findings
of the present study are not entirely consistent with previous research because previous research
in diabetics with peripheral neuropathy suggested that in the presence of peripheral neuropathy,
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gait patterns should undergo significant changes; in this study only gait velocity and step length
were significantly different. A plausible reason for the inconsistencies between the results of the
present study and previous research may be due to several limitations. First, the presence of
CIPN was determined by the Common Terminology Criteria for Adverse Events (CTCAE)
version 4.0, in which patients can simply report numbness and tingling; so, the extent of the
damage to peripheral nerves was not quantified nor was the fiber types affected by the
chemotherapy agents specified. This is a significant limitation because the types of fibers
affected by the chemotherapy agents may explain why only velocity was found to be
significantly different. While type Ia, type Ib, and type 2 fibers may be the primary fibers
providing afferent feedback for the reflex arcs involved in gait mediation, these may not be the
main fibers affected by the chemotherapy agents (Argyriou et al., 2012; Mantyh, 2006).
In the literature it has been suggested that unmyelinated C fibers and myelinated Aδ
fibers, which are sensory fibers called nociceptors, may in fact be the primary targets on which
the chemotherapy agents exert their neurotoxic effects. Unmyelinated C fibers and myelinated
Aδ fibers can detect a variety of stimulus that can be both physical and chemical in nature.
Although primary afferent neurons have their cell bodies in the dorsal root ganglion and transmit
information from peripheral tissue to the spinal cord, unmyelinated C and myelinated Aδ fibers
only project to superficial layers of the spinal cord. Primary afferent sensory fibers can detect
nonnoxious sensations, such as light touch, vibration, and proprioceptive stimuli, whereas
unmyelinated C and myelinated Aδ fibers can detect noxious chemical, thermal, and mechanical
stimuli. It is also postulated that the unmyelinated C and myelinated Aδ fibers generate the pain
that is caused by antitumor therapies, such as chemotherapies that include taxanes and platinum-
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based compounds, causing chemotherapy-induced peripheral neuropathy (Argyriou et al., 2012;
Mantyh, 2006).
Previous research supports this hypothesized mechanism of the neurotoxic effects of
chemotherapy on the nerves, as cancer patients diagnosed with CIPN have various sensory signs
and symptoms that start with paresthesia and numbness in the hands and vibratory perception,
along with disabling pain, which suggests involvement of small, unmyelinated nerve fibers
(Hilkens et al., 1997). However, Visovsky and Daly (2004) found no effect on deep tendon
reflex using Babinski’s reflex hammer, which suggests that the type Ia, type Ib, and type 2
afferent nerves that innervate Golgi tendon organs and muscles spindles and their corresponding
reflex mechanisms are intact. This is a significant observation because it is proposed in the
literature that these three reflex mechanisms are most responsible for mediating gait (Dietz,
2002).
Conversely, a more recent study by Kneis and colleagues (2015) found that cancer
patients who received taxane chemotherapy demonstrated prolonged H-reflex latency, as well as
changes in H-reflex sensitivity associated with modulated spinal excitability. These findings
suggest that chemotherapy agents may have a neurotoxic effect on the Ia afferent fibers of
muscle spindle and Golgi tendon organs that are part of the monosynaptic reflex arcs. The
authors also noted that cancer patients with CIPN displayed increased postural sway. However,
the study did not find a correlation between H-reflex latency and center-of-pressure sway path.
Therefore, although evidence supports that unmyelinated C and myelinated Aδ fibers may
experience a neurotoxic effect due to chemotherapy, and possibly even type Ia afferent fibers part
of reflex arcs, the primary fibers that experience the neurotoxic effect of thermotherapy may not
be prime gait mediators, which may explain why there were no significant differences found in
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spatial and temporal gait parameters other than velocity between those with CIPN and their
healthy and morphologically matched controls (Kneis et al., 2015).
A second explanation for the inconsistencies in the present study with previous research
is that although unmyelinated C and myelinated Aδ fibers may experience a neurotoxic effect
due to chemotherapy, individuals may develop compensatory behaviors due to the loss of
sensory input caused by CIPN. Gait is the result of afferent information from visual, vestibular,
and proprioceptive systems. These three system do not operate independently; the body uses
somatosensory information from all bodily sources in order to shape functional movement.
When the contribution of somatosensory information is attenuated, or lost, such as in the case of
peripheral neuropathy, the vestibular system provides a greater contribution to posture and
balance (Horak & Hlavacka, 2001; Simoneau et al., 1995).
Mergner, Huber, and Becker (1997) postulated that vestibular information descends down
body segments where it meets and fuses with ascending somatosensory information, combining
to provide coordinates as to where the body is in space (Mergner & Rosemeier, 1998). Thus,
when somatosensory information is lessened, the body still receives vestibular sensory
information to regulate body movement. The vestibular system may primarily mediate the trunk
during gait, which is important to note because the trunk may have a greater influence on gait
stability then lower body segments because the trunk has a larger body mass. Therefore, it needs
a greater amount of stability while walking (Creath, Kiemel, Horak, & Jeka, 2008; Deshpande &
Zhang, 2014). Furthermore, the vestibular system may be a greater mediator of stability during
gait. Thus, although CIPN patients may have attenuate somatosensory afferent feedback, more
noticeable changes in spatiotemporal gait parameters other than gait velocity were not found due
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to the intact vestibular information that is critical for trunk control and walking accuracy
(Deshpande & Zhang, 2014).
Although previous research has established the importance of afferent feedback for the
mediation of gait, the extent of the mediation remains unknown. Decreased gait velocities may
not only be due to the neurotoxic effect of the chemotherapy agents but also due to the presence
of pain. Individuals with CIPN commonly report symptoms that include burning, muscle aches,
sensitivity to cold, and feelings of “walking on hot coals” or “sandpaper on the bottom of your
feet”; cancer patients experiencing CIPN often report varying degrees of pain (Tofthagen, 2010;
p. E25). The presence of pain alone is associated with a decrease in walking velocity; a recent
study that evaluated Gait parameters in individuals with foot pain related to gout found that those
individuals with gout-related foot pain walked significantly slower (Stewart, 2016). A study by
van den Hoorn, Hug, Hodges, Bruijn, and van Dieën (2015) investigated if nociceptive
stimulation and induced pain affect gait stability. Previous research suggests that
musculoskeletal pain is associated with fall risk and has a negative impact on stability (Asai,
Misu, Sawa, Doi, & Yamada, 2015; de Zwart et al., 2015; Kitayuguchi, Kamada, Okada,
Kamioka, & Mutoh, 2015; Ross, Mavor, Brown, & Graham, 2015).
It is hypothesized that individuals who are experiencing pain will adapt their motor
program to protect injured tissues. The adaptations may increase joint stability because the
muscles are less responsive in order to reduce pain. For example, if pain is presence in the calf,
the calf muscle may not be as responsive, as indicated by a decrease in contractions, resulting in
a decrease in the range of motion the ankle joint may undergo during gait (Hodges & Tucker,
2011; Lund, Donga, Widmer, & Stohler, 2011; van Dieën, Selen, & Cholewicki, 2003). The
combination of increased joint stiffness, decreased responsiveness of the tissues, and the
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presence of impaired nociceptive afferent fibers, with decreasing proprioceptive acuity and the
inability to regulate force, may result in a decrease in stability (Brumagne, Cordo, Lysens,
Verschueren, & Swinnen, 2000; Descarreaux, Blouin, & Teasdale, 2005; Hodges et al., 2011;
Lee, Cholewicki, Reeves, Zazulak, & Mysliwiec, 2010; Matre, Arendt-Nielsen, & Knardahl,
2002; Salomoni, Ejaz, Laursen, & Graven-Nielsen, 2013; van den Hoorn, Bruijn, Meijer,
Hodges, & van Dieën, 2012).
Van den Hoorn and colleagues (2015) found that nociceptive irritation of the calf and
back muscled decrease gait stability at low walking speed. Greater effects were seen in the calf
than in the low back, which puts forth the idea that the gait adaptations may depend on the
specific muscle. The findings of van den Hoorn and colleagues that the presence of pain can
affect gait stability at lower walking speeds and that the specific muscle affected also plays a
critical role are important to note because cancer patients with CIPN, as well as individuals with
diabetic peripheral neuropathy (DPN), often report pain in their lower legs, specifically their feet
and calves (Tofthagen, 2010). Thus the presence of pain in the lower extremities by individuals
with CIPN is significant because the decrease in gait speed could be caused not by the decrease
in afferent feedback but simply by the presence of pain because it is suggested that individuals
who are experiencing pain may undergo motor adaptations to protect the painful/injured tissues,
resulting in a decrease in gait velocity (Hodges & Tucker, 2011; Lund et al., 2011; van Dieën et
al., 2003).
Lastly, the slower walking velocities may not be due to the attenuated afferent feedback
or presence of pain but may be due to a deconditioning effect experienced by cancer patients that
has been documented to occur while undergoing treatment for cancer.
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A stable and successful gait that allows individuals to safely navigate their environment
requires an appropriate amount of muscular strength and joint range of motion (Neumann, 2002;
Shumway-Cook & Woollacott, 2012). Chemotherapy and radiation therapy may often cause
muscle atrophy and muscles weakness (Mustian et al., 2009). Certain chemotherapy agents may
cause pulmonary fibrosis and abnormal development of pulmonary tissue, resulting in coughing,
dyspnea, fatigue, and overall decreased functional capacity (Schneider et al., 2003). It is
estimated that 30% of cancer survivors will decrease their physical activity levels upon receiving
a cancer diagnosis, and up to 70% of cancer survivors do not meet the U.S national
recommendations for exercises and physical activity (Blanchard, Courneya, & Stein, 2008;
Blanchard, Denniston, & Backer, 2003). Thus, due to the decreased amount of physical activity
and the effects of cancer therapies, many cancer patients experience a deconditioning effect,
which could cause slower gait velocities and decrease step length. Ko, Stenholm, Metter, and
Ferrucci (2012) found that a decrease in gait speed was associated with decreases in range of
motion within the hip, knee, and ankle. Ko and colleagues (2012) also found that a slower gait
velocity was also associated with a decrease in maximum isokinetic knee extensor strength,
suggesting that muscle strength is a contributing factor in gait velocity. Thus, as the body
becomes weaker and stiffer, as indicated by decrease joint range of motion, gait will also become
slower. This association between gait and a deconditioned body may also explain the slower gait
in those with CIPN because the participants in the present study were nonexercisers as defined
by the inclusion criteria, which required that they not participate in more than 150 min of regular
physical activity per week. The chemotherapy treatments undergone by those with CIPN may
have caused a deconditioning effect, resulting in loss of muscle strength that may also have been
a contributing factor to the significantly slower walking velocities. However, the present study
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did not evaluate and quantify this possible deconditioning effect and compare the physical status
of those with CIPN to those without CIPN, as well as the physical condition between the two
groups.
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Chapter V1
SUMMARY AND CONCLUSIONS
As improvements continue to be made in screening measures and treatment options, the
number of cancer survivors will increase. However, many cancer survivors will face long-term
physical health effects and functional impairments due to chemotherapy-induced peripheral
neuropathy (CIPN). Neuropathy is associated with postural and functional impairments. In
cancer patients with CIPN, impairments may manifest as gait or balance disorders, which may be
linked to higher rates of falling, limiting activities of daily living. However, the exact nature in
which CIPN affects the spatiotemporal mechanism of gait remains largely unknown (Kneis et al.,
2015).
The results of this study indicate that cancer patients with CIPN displayed a slower
walking velocity and shorter step length, resulting in a higher risk of falls, compared to healthy,
age and morphologically matched controls. Additional gait patterns, such as step time, base of
support, swing time, single support time, and double support time, were not significantly
different. Also, while the mean TUG score for CIPN patients was not only significantly greater,
but was also above the clinical fall risk cut off of 10.7 s, indicating fall risk. Both gait speed and
step length are key indicators for fall risk; slower gait velocities and shorter step lengths are
associated with increased fall risk (Espy et al., 2010; Schult et al., 2013; Verghese et al., 2009)
Despite the findings that gait velocity and step length is significantly reduced in
individuals with CIPN, there were several limitations to the present study. First, the presence of
CIPN was determined by the Common Terminology Criteria for Adverse Events (CTCAE)
Version 4.0, in which patients can simply report numbness and tingling. Therefore, the extent of
the damage to peripheral nerves was not quantified. Secondly, it remains unknown if the cause
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of decreased gait velocity was due to the neurotoxic effect of the chemotherapy agents on the
afferent nerve fibers that provide gait mediation or if the decreased gait velocity was due to the
presence of neuropathic pain, or a combination of both. Lastly, gait velocity may also have been
slowed due to a deconditioning effect caused by the treatment process. But this possible
deconditioning effect was not accounted for in the present study.
Future research studies should address the limitations of the present study and investigate
the effect (if any) of the deconditioning caused by chemotherapy treatments on gait velocity.
Future studies might also investigate the timing during a chemotherapy regimen of taxane or
oxaliplatin, during which the gait velocity may decrease. Future research might also investigate
other chemotherapeutic agents that case CIPN, such as vincristine, and if the same changes in
gait velocity occur.
In conclusion, the finding that gait velocities and step length were significantly slower in
individuals with CIPN, as well as increased risk of falls as assessed by the TUG test, is very
meaningful because slower gait velocities and shorter step lengths are associated with increased
fall risk, which was demonstrated by the CIPN participant’s mean TUG score.
Although this significant association was found, it remains unknown if the cause of the
decreased gait velocity, shortened step length, and increased risk of falls as assessed by the TUG
test, was the neurotoxic effect of the chemotherapy agents on the afferent nerve fibers that
provide gait mediation or if the decreased gait velocity was due to the presence of neuropathic
pain or a deconditioning effect caused by the treatment process. Nevertheless, the study findings
aid in understanding the effects of chemotherapy-induced peripheral neuropathy on
spatiotemporal gait parameters in cancer patients post chemotherapy drug treatment and assist in
addressing functional limitations in CIPN patients
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